# **SYSTEMATIC REVIEW AND META-ANALYSIS**

Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension

Sonali R. Gnanenthiran , PhD; Claudio Borghi , MD; Dylan Burger, PhD; Bruno Caramelli , PhD; Fadi Charchar, PhD; Julio A. Chirinos , PhD; Jordana B. Cohen , MD; Antoine Cremer, PhD; Gian Luca Di Tanna , PhD; Alexandre Duvignaud, PhD; Daniel Freilich, MD; D. H. Frank Gommans, PhD; Abraham E. Gracia-Ramos , MD; Thomas A. Murray , PhD; Facundo Pelorosso, PhD; Neil R. Poulter , PhD; Michael A. Puskarich , MD; Konstantinos D. Rizas, MD; Rodolfo Rothlin , MD; Markus P. Schlaich , MD; Michael Schreinlecher, MD; Ulrike Muscha Steckelings , PhD; Abhinav Sharma , PhD; George S. Stergiou , MD; Christopher J. Tignanelli, MD; Maciej Tomaszewski , MD; Thomas Unger, PhD; Roland R. J. van Kimmenade, PhD; Richard D. Wainford , PhD; Bryan Williams , MD; Anthony Rodgers, PhD; Aletta E. Schutte , PhD; on behalf of the COVID-METARASI Consortium\*

**BACKGROUND:** Published randomized controlled trials are underpowered for binary clinical end points to assess the safety and efficacy of renin-angiotensin system inhibitors (RASi) in adults with COVID-19. We therefore performed a meta-analysis to assess the safety and efficacy of RASi in adults with COVID-19.

**METHODS AND RESULTS:** MEDLINE, EMBASE, ClinicalTrials.gov, and the Cochrane Controlled Trial Register were searched for randomized controlled trials that randomly assigned patients with COVID-19 to RASi continuation/commencement versus no RASi therapy. The primary outcome was all-cause mortality at  $\leq$ 30 days. A total of 14 randomized controlled trials met the inclusion criteria and enrolled 1838 participants (aged 59 years, 58% men, mean follow-up 26 days). Of the trials, 11 contributed data. We found no effect of RASi versus control on all-cause mortality (7.2% versus 7.5%; relative risk [RR], 0.95; [95% CI, 0.69–1.30]) either overall or in subgroups defined by COVID-19 severity or trial type. Network meta-analysis identified no difference between angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers. RASi users had a non-significant reduction in acute myocardial infarction (2.1% versus 3.6%; RR, 0.59; [95% CI, 0.33–1.06]), but increased risk of acute kidney injury (7.0% versus 3.6%; RR, 1.82; [95% CI, 1.05–3.16]), in trials that initiated and continued RASi. There was no increase in need for dialysis or differences in congestive cardiac failure, cerebrovascular events, venous thromboembolism, hospitalization, intensive care admission, inotropes, or mechanical ventilation.

**CONCLUSIONS:** This meta-analysis of randomized controlled trials evaluating angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers versus control in patients with COVID-19 found no difference in all-cause mortality, a borderline decrease in myocardial infarction, and an increased risk of acute kidney injury with RASi. Our findings provide strong evidence that RASi can be used safely in patients with COVID-19.

Key Words: acute kidney injury angiotensin II receptor blockers angiotensin-converting enzyme inhibitors COVID-19 hypertension renin-angiotensin system inhibitors

Correspondence to: Aletta E. Schutte, PhD, School of Population Health, University of New South Wales, Kensington Campus, High Street, Sydney, New South Wales 2052, Australia. Email: a.schutte@unsw.edu.au

<sup>\*</sup>A complete list of the COVID-METARASI consortium members can be found in the Supplemental Material.

Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.122.026143

For Sources of Funding and Disclosures, see page 10.

<sup>© 2022</sup> The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. *JAHA* is available at: www.ahajournals.org/journal/jaha

## **CLINICAL PERSPECTIVE**

### What Is New?

 There was an almost 2-fold increased risk of acute kidney injurty associated with reninangiotensin system inhibitors (RASi) in patients hospitalized with acute COVID-19 in hospitalized patients (7.0% versus 3.6%; relative risk, 1.82; [95% CI, 1.05–3.16]). The overall event rate was low, but effects were consistent across trials that initiated and those that continued RASi, but was not associated with an increased need for dialysis or mortality at short-term follow-up.

### What Are the Clinical Implications?

- Evidence suggests that patients who are using RASi should continue taking their medication as prescribed; the overall cardiovascular benefits of these drugs are overwhelming, and early alerts of potential increased risk in patients with COVID-19 have been silenced; similarly, clinicians should not be hesitant to initiate RASi treatment in patients with COVID-19.
- RASi can still be safely used in patients with COVID-19 while being aware of an increased risk of acute kidney injury in hospitalized patients.
- There does not appear to be increased risk of acute kidney injury in outpatients, which is where the vast majority of COVID-19 is managed, and longer term follow-up is needed to investigate renal outcomes and whether there may even be benefits of RASi to slow the progression of proteinuric chronic kidney disease in such patients.

### Nonstandard Abbreviations and Acronyms

- ACE2 angiotensin-converting enzyme 2
- AKI acute kidney injury
- RASi renin-angiotensin system inhibitors

Renin-angiotensin system inhibitors (RASi), including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are the most widely prescribed antihypertensive treatments used by hundreds of millions of people worldwide.<sup>1</sup> RASi are not only first-line agents for the treatment of hypertension but also are the cornerstone for treating conditions such as heart failure, coronary heart disease, diabetes, and chronic kidney disease. It has been suggested that RASi therapy may upregulate the expression of the angiotensin-converting enzyme 2 (ACE2) receptor,<sup>2,3</sup> which is the functional receptor for SARS-CoV-2,<sup>4</sup> the virus responsible for the COVID-19 pandemic. However, ACE2 upregulation has not been consistently demonstrated,  $^5$  nor has it been shown to affect the function of RASi.  $^6$ 

The BRACE CORONA (blockers of angiotensin receptor and angiotensin-converting enzyme inhibitors suspension in hospitalized patients with coronavirus infection) randomized trial<sup>7</sup> in patients hospitalized with mild-moderate COVID-19 suggested that days alive outside of hospital were equivalent in those continuing ACEIs/ARBs compared with those who had therapy suspended. Similarly compared with discontinuation of RASi, the REPLACE COVID (the randomized elimination or prolongation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in coronavirus disease 2019) trial found that continuation of RASi had no effect on a composite global rank score as a marker for COVID-19 severity.<sup>8</sup> In comparison, the ACE-COVID trial demonstrated that RASi discontinuation may lead to a more rapid and improved recovery from COVID-19.9 Most randomized controlled trials (RCTs) starting ARB therapy have also failed to demonstrate any difference compared with those not randomized to RASi therapy.<sup>10–15</sup> These trials, together with multiple others, are small to moderate in size, with many unable to meet their recruitment targets, and are insufficiently powered to answer questions regarding binary clinical end points or subgroup populations. Animal and observational studies have provided conflicting data, including concerns that RASi-induced upregulation of ACE2 receptor expression may increase viral cell entry, whereas other studies have suggested that therapies may provide protective benefits<sup>2,3,16</sup> or have no effect on ACE2 expression.<sup>17</sup> In response to these uncertainties, numerous RCTs have been initiated to determine the short-term safety of RASi in patients with COVID-19. International hypertension, cardiology, and nephrology societies have consistently recommended that patients continue RASi therapy during the COVID-19 pandemic on the basis of the strong and well-documented evidence on their cardiovascular protective effects, but identified a need for more reliable human data.<sup>18–22</sup> We therefore performed a meta-analysis of RCTs in patients with COVID-19 to assess the safety and efficacy of RASi therapy compared with controls without RASi at short-term follow-up.

### **METHODS**

# Meta-Analysis Design and Selection of Trials

Our meta-analysis and search strategy were reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis for protocol recommendations.<sup>23</sup> The methods of this review were previously published<sup>24</sup> and will be outlined here in brief. Using the Cochrane Collaboration guidelines,<sup>25</sup> electronic searches of MEDLINE (1996–present), EMBASE (1996–present), the Cochrane Central Register of Controlled Trials (most recent edition), and ClinicalTr ials.gov were performed in June 2021 to identify RCTs that meet the inclusion criteria.

Trials with the following criteria were included: (1) RCTs recruiting between March 2020 and June 2021, (2) patients aged ≥18 years; (3) laboratory-confirmed SARS-CoV-2 infection, (4) comparison of patients randomly assigned to RASi versus no RASi therapy (this includes trials that investigate continuation versus cessation of RASi among patients currently treated with RASi and trials that report initiation of RASi versus control in those not currently treated with such therapies), (5) findings reported in English, and (6) oral administration of RASi therapies. Two reviewers (S.R.G. and A.E.S.) independently performed study selection, quality assessment, and data extraction. Data extraction included information regarding study design, participants, methods, interventions, and outcome measures. End points were allcause mortality, acute myocardial infarction, congestive cardiac failure, venous thromboembolism, hospitalization, admission to intensive care, mechanical ventilation, hypotension requiring inotropes, and acute kidney injury (AKI; defined according to the Kidney Disease Improving Global Outcomes criteria)<sup>26</sup> at short-term follow-up (defined as ≤30 days). Standardized grouped tabular deidentified data were requested from trialists. A quality assessment of each trial was performed by 2 authors (S.R.G. and A.E.S.) using the Cochrane Collaboration risk of bias tool.<sup>25,27</sup> Each included trial was approved by an institutional review committee, and the participants gave informed consent.

### **Statistical Analysis**

Trial-specific outcome data were pooled. For binary outcomes, risk ratios and 95% Cls were estimated. Head-to-head meta-analyses were performed by the Mantel-Haenszel fixed-effects models,<sup>28</sup> with key results presented using forest plots. A 2-tailed P value of 5% was used for hypothesis testing. Small study effect was assessed by visual inspection of funnel plots and by formal regression-based Egger tests.<sup>29</sup> Quantitative heterogeneity has been explored by prespecified subgroup analyses and fitting univariable meta-regression with the percentage loss to follow-up as a fixed-effect covariate.<sup>24</sup> A fixed-effects analysis was used unless there was significant heterogeneity (as evidenced by  $l^2$  >50% and quantitatively large variation), in which case random-effects analysis was performed instead.<sup>28</sup> Sensitivity analyses to account for zero and small counts in some trials were performed using the reciprocal of the sample size of the opposite arm.<sup>30</sup> To assess the relative efficacy of ACEIs versus ARBs (versus control), we also fitted a frequentist randomeffects network meta-analysis. We reported resulting rankograms and P scores<sup>31</sup>: these allow rank treatments on a continuous scale (with a 0–1 range, the higher the better) and are the frequentist analog of the surface under the cumulative ranking curve.

Analyses were conducted using Review Manager 5.3 software (Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration), Comprehensive Meta-Analysis V3 (Biostat, Englewood, NJ), and the package netmeta in R.<sup>32</sup>

The authors declare that all supporting data are available in the article and its supplemental files.

### RESULTS

Of 45 articles identified through a systematic search and 23 trials on ClinicalTrials.org, 14 RCTs met the inclusion criteria (Table 1, Figure 1). Of the trials, 11 provided grouped tabular data. A total of 1838 patients with a mean follow-up of 26 days were enrolled, including sites in Argentina, Austria, Brazil, Canada, France, Germany, Iran, Mexico, the Netherlands, and the United States. Of these, 5 trials evaluated the continuation versus discontinuation of RASi therapies in those already on such therapies (n=1079), and 9 trials involved initiation of RASi in those naïve to therapy (n=759). All 9 trials initiating RASi therapies involved commencement of ARBs (n=5 telmisartan, n=3 losartan, n=1 valsartan).

### **Study Quality**

The RCTs were of high quality as assessed by the Cochrane Collaboration risk of bias tool (Table S1, Figure S1). There were 4 placebo-controlled, doubleblinded RCTs, 9 open-label trials, and 1 doubleblinded RCT comparing ARB versus amlodipine. Of these, 12 trials were conducted in patients hospitalized with COVID-19 and 2 trials recruited outpatients. All trials used random sequence generation and were judged as being low risk of selection bias. The doubleblinded trials were judged as being at low risk of allocation concealment and performance biases, whereas the open-label trials were judged as having moderate risk of these biases. Most trials were at low risk of detection bias and attrition bias, with only 1 trial having a loss to follow-up of >10%. All trials had a low risk of reporting bias.

### **Baseline Clinical Characteristics**

Baseline clinical characteristics of the intervention and control groups are described in Table 2, indicating comparable profiles. The mean age of the population was 58.8 years, and 57.6% were men. Hypertension was prevalent in 75.5%, diabetes in 28.5%, cardiovascular

Trial name	Country	Inclusion criteria	Intervention	Control	No.	Follow-up, d
ACEI-COVID <sup>9</sup>	Germany; Austria	<ul> <li>Symptomatic COVID-19</li> <li>ACEI/ARB use before admission</li> <li>Hemodynamically stable</li> </ul>	Continue ACEI/ ARB	Discontinue ACEI/ARB	204	30
BRACE CORONA <sup>7</sup>	Brazil	<ul><li>Hospitalization with COVID-19</li><li>ACEI/ARB use before admission</li></ul>	Continue ACEI/ ARB	Discontinue ACEI/ARB	659	30
RAAS-COVID <sup>15</sup>	Canada	Hospitalization with COVID-19     ACEI/ARB use before admission	Continue ACEI/ ARB	Discontinue ACEI/ARB	46	30
REPLACE-COVID <sup>8</sup>	United States, Canada, Mexico, Sweden, Peru, Bolivia, and Argentina	<ul> <li>Hospitalization with COVID-19</li> <li>ACEI/ARB use before admission</li> </ul>	Continue ACEI/ ARB	Discontinue ACEI/ARB	152	5
SWITCH-COVID	Brazil	<ul> <li>Hospitalization with COVID-19</li> <li>Hypertension requiring ACEI/ARB use before admission</li> </ul>	Continue ACEI/ ARB	Discontinue ACEI/ARB	18	30
ALPS-COVID IP14	United States	<ul> <li>Hospitalization with a respiratory SOFA ≥1 and increased oxygen requirement compared with baseline among those on home O<sub>2</sub></li> </ul>	Losartan	Placebo	205	28
ALPS-COVID OP13	United States	<ul><li>Outpatients not requiring hospitalization</li><li>Symptomatic (within 24 h of informed consent)</li></ul>	Losartan	Placebo	117	28
ARB use to minimize progression to respiratory failure <sup>11</sup>	United States	<ul> <li>Mild to moderate hypoxia</li> <li>SpO<sub>2</sub>&lt;96% on ≥L/min O<sub>2</sub> by nasal cannula but not requiring mechanical ventilation</li> </ul>	Losartan	Standard care	31	10
COVERAGE-France	France	<ul> <li>No indication for hospitalization or acute oxygen therapy</li> <li>Age ≥60 years or 50 to 59 years with</li> <li>At least 1 of the following risk factors: hypertension, obesity, diabetes, CAD, CCF, stroke, COPD, CKD, solid tumors, or malignant blood diseases that are progressive or were diagnosed &lt;5 years ago or immunodeficiency</li> </ul>	Telmisartan	Vitamin supplement	69	14
COVID MED	United States	Hospitalized patients	Losartan	Placebo	12	30
Evaluation of the effect of losartan in COVID-19 <sup>12</sup>	Iran	<ul> <li>Hospitalized patients</li> <li>Hypertension: systolic BP 130 to 140mmHg and diastolic BP 85 to 90mmHg who were managed by nonpharmacological strategies or were newly diagnosed</li> </ul>	Losartan	Amlodipine	80	30
PRAETORIAN-COVID	The Netherlands	Hospitalized patients	Valsartan	Placebo	23	14
STAR-COVID	Mexico	Hospitalized with hypoxic respiratory failure: SpO₂≤94% on room air or tachypnea (respiratory rate≥22 breaths/min)	Telmisartan	Standard care	64	30
Telmisartan for treatment of patients with COVID-19 <sup>10</sup>	Argentina	<ul><li>Hospitalization with COVID-19</li><li>Symptomatic COVID-19</li></ul>	Telmisartan	Standard care	141	30

ACEI indicates angiotensin-converting enzyme inhibitor; ACEI-COVID, the stopping ACE-inhibitors in COVID-19 trial; ALPS-COVID OP, angiotensin receptor blocker based lung protective strategy for COVID-19 outpatient trial; ALPS-COVIDIP, Angiotensin receptor blocker based lung protective strategy for COVID-19 outpatient trial; ALPS-COVIDIP, Angiotensin receptor blocker based lung protective strategy for COVID-19 outpatient trial; ALPS-COVIDIP, Angiotensin receptor blocker based lung protective strategy for COVID-19 inpatient trial; ARB, angiotensin II receptor blocker; BP, blood pressure; BRACE CORONA, blockers of angiotensin receptor and angiotensin-converting enzyme inhibitors suspension in hospitalized patients with coronavirus infection; CAD, coronary artery disease; CCF, congestive cardiac failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COVERAGE-France, randomized trial to evaluate the safety and efficacy of outpatient treatments to reduce the risk of worsening in individuals with COVID-19 with risk factors; COVID MED, comparison of therapeutics for hospitalized patients infected with SARS-COV-2; PRAETORIAN-COVID, randomized trial with valsartan for prevention of acute respiratory distress syndrome in hospitalized patients with SARS-COV-2 Infection Disease; RAAS-COVID, renin-angiotensin aldosterone system inhibitors in COVID-19; REPLACE COVID, the randomized elimination or prolongation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in coronavirus disease 2019; SOFA, sequential organ failure assessment; STAR-COVID, telmisartanin respiratory failure due to COVID-19; and SWITCH-COVID, switch of renin-angiotensin system inhibitors in patients with COVID-19.

disease in 10.4%, obesity in 35.8%, and chronic obstructive pulmonary disease in 10.8%. COVID-19 severity ranged from mild (46.6%) or moderate (44.2%) to severe (9.2%). Of those patients recruited, 21.6% were either current or past smokers.

### Primary Outcome All-Cause Mortality

A total of 14 trials provided all-cause mortality data (n=1838; Figure 2A), with 12 trials reporting a total of

4




Figure 1. Flowchart of study selection methodology.

135 deaths. We found no effect of RASi versus control on all-cause mortality (7.2% versus 7.5%; relative risk [RR], 0.95; [95% CI, 0.69–1.30]; *I*<sup>2</sup>=15%; *P*=0.73). When analyzed by trial type, there was no significant difference between trials that compared RASi initiation (RR, 0.72; [95% Cl, 0.46-1.14]; P=0.16) versus continuation (RR, 1.24; [95% CI, 0.78-1.96]; P=0.36; P=0.28 for subgroup difference; Figure S2). We also found no difference in mortality by placebo control versus open-label trials, location of trial, or COVID-19 severity (Figures S3 through S5). In the ARB class, there was no difference between the different drugs (Figure S6). There was no significant publication bias as assessed by Egger regression testing (P=0.86), although inspection of the plot suggested an underrepresentation of trials showing benefit with RASi therapy (Figure S7).

Sensitivity analyses demonstrated that there were no effects on all-cause mortality across subgroups based on age, sex, or ethnicity (Figures S8 through S10), although there was a nonsignificant trend to increased mortality among the White population with RASi therapy (RR, 1.52; [95% CI, 0.85–2.72]; *P*=0.16). Analyses accounting for the small counts in some trials also did not change the results (Table S2). There were also no between-group differences in all-cause mortality for those on RASi compared with control when stratified by the presence or absence of hypertension, diabetes, cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, smoking status, or obesity (Figures S11 through S17). Although the largest trial (BRACE-CORONA) accounted for a large proportion of participants, an analysis excluding this trial did not change the results (RR, 0.93; [95% CI, 0.66–1.31]). Meta-regression analysis of trials according to percentage loss to follow-up demonstrated that trials with a higher loss to follow-up overestimated mortality benefit with RASi (coefficient, -0.165; [95% CI, -0.281 to -0.050]; P=0.005; Figure S18).

Network meta-analysis comparing control to ACEIs versus ARBs demonstrated no statistically significant differences between ACEIs and ARBs, but ACEIs were associated with a worse mortality effect with a *P* score of 0.089 compared with *P* scores of 0.72 and 0.69 for ARBs and control, respectively (Figures S19 and S20). In particular, we found the RR of ARBs versus ACEIs of 0.60 (95% CI, 0.29–1.23) and the RRs versus placebo for ACEIs and ARBs equal to 1.65 (95% CI, 0.78–3.48) and 0.99 (95% CI, 0.62–1.59), respectively (overall inconsistency  $I^2$ =28.3%; test of homogeneity *P* value=0.15).

### Secondary Outcomes Myocardial Infarction

A total of 10 trials collected acute myocardial infarction outcomes (n=1546; Figure 2B): 3 trials that compared continuation versus discontinuation of RASi in people with preexisting hypertension and/or cardiovascular disease reported a total of 44 events. Pooling of these studies suggest a substantial but nonstatistically

Table 2.	<b>Baseline Clinical Characteristics of Total Cohort</b>
(N=1838)	

[		Í.
	Renin-angiotensin system inhibitors (n=917)	Control (n=921)
Mean age, y	58.6	58.9
Sex, n (%)	` 	
Male sex	526/917 (57.4)	532/921 (57.8)
Female sex	391/917 (42.6)	389/921 (42.2)
Past medical history, n (%)	` 	
Hypertension	669/889 (75.3)	679/897 (75.7)
Diabetes	266/917 (29.0)	258/921 (28.0)
Hypercholesterolemia	115/329 (35.0)	94/325 (28.9)
Cardiovascular disease	90/856 (10.5)	89/867 (10.2)
Obesity	164/451 (36.4)	159/450 (35.3)
Chronic kidney disease	48/759 (6.3)	44/763 (5.8)
Chronic obstructive pulmonary disease	64/586 (10.9)	61/572 (10.7)
Smoking, n (%)		
Ever smoked	109/514 (21.2)	113/516 (21.9)
Nonsmoker	405/514 (78.8)	403/516 (78.1)
COVID-19 severity, n (%)		
Mild	343/722 (47.5)	324/709 (45.7)
Moderate	311/722 (43.0)	321/709 (45.3)
Severe	68/722 (9.4)	64/709 (9.0)

Cardiovascular disease defined as established coronary artery disease, heart failure, arrythmia, and/or stroke; chronic kidney disease defined as estimated glomerular filtration rate <60 mL/min per  $1.73 \, \text{m}^2$ .

significant reduction in acute myocardial infarction with RASi compared with control (2.1% versus 3.6%; RR, 0.59; [95% CI, 0.33–1.06];  $l^2$ =9%; P=0.078).

#### **Coronary Revascularization**

Data were collected from 8 trials (n=841), but there were no coronary revascularization events reported in the RASi and control groups.

#### **Cerebrovascular Accidents**

A total of 10 trials provided cerebrovascular outcomes (n=1546; Figure S21), with 2 trials reporting events. A total of 8 cerebrovascular events were

observed. There was no significant difference in cerebrovascular events with RASi compared with control (0.6% versus 0.4%; RR, 1.62; [95% Cl, 0.43–6.15];  $I^2$ =0%; P=0.48).

#### **Congestive Cardiac Failure**

A total of 9 trials provided congestive cardiac failure outcomes (n=1341; Figure S22), with 3 trials reporting a total of 41 heart failure events. There were no statistically significant between-group differences in congestive cardiac failure on RASi compared with control (2.8% versus 3.3%; RR, 0.71; [95% CI, 0.16–3.17];  $l^2$ =60%; P=0.66).

#### Venous Thromboembolism

Data were available from 9 trials (n=1500; Figure S23), with 3 trials reporting 16 venous thromboembolism events. There was no difference in the rate of thromboembolism between the groups (1.2% versus 0.9%; RR, 1.18; [95% CI, 0.45–3.05];  $l^2$ =0%; P=0.74).

#### Hospitalization

There were only 2 small outpatient trials<sup>13,33</sup> that reported hospitalization rates for COVID-19 (n=186; Figure S24). A total of 9 hospitalization episodes were observed. There was no significant difference in rates of hospitalization detected between those on RASi compared with control (6.4% versus 3.3%; RR, 1.92; [95% CI, 0.50–7.35];  $I^2$ =0; P=0.34).

### Intensive Care Admission

A total of 11 trials collected intensive care admission outcomes (n=1035; Figure 2C), with 10 trials reporting a total of 175 admissions. There was no difference in admission to intensive care between those on RASi compared with control (17.0% versus 16.9%; RR, 1.00; [95% CI, 0.77–1.30];  $l^2=2\%$ ; P=0.98). Analysis comparing trials that commenced versus those that continued/discontinued RASi also did not demonstrate differences in intensive care admission rates (P=0.91 for subgroup differences; Figure S25).

#### Figure 2. Outcomes at short-term follow-up (≤30 days).<sup>7-15</sup>

ACEI-COVID, the stopping ace-inhibitors in COVID-19 trial; ALPS-COVID IP, angiotensin receptor blocker based lung protective strategy for COVID-19 inpatient trial; ALPS-COVID OP, angiotensin receptor blocker based lung protective strategy for COVID-19 outpatient trial; BRACE CORONA, blockers of angiotensin receptor and angiotensin-converting enzyme inhibitors suspension in hospitalized patients with coronavirus infection; COVERAGE-France, randomized trial to evaluate the safety and efficacy of outpatient treatments to reduce the risk of worsening in individuals with COVID-19 with risk factors; COVID MED, comparison of therapeutics for hospitalized patients infected with SARS-CoV-2; M-H indicates Mantel–Haenszel; PRAETORIAN-COVID, randomised clinical trial with valsartan for prevention of acute respiratory distress syndrome in hospitalised patients with SARS-COV-2 infection disease; RAAS-COVID, renin-angiotensin aldosterone system inhibitors in COVID-19 trial; RASi, renin-angiotensin system inhibitors; REPLACE COVID, the randomized elimination or prolongation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in coronavirus disease 2019; STAR-COVID, telmisartan in respiratory failure due to COVID-19; and SWITCH-COVID, switch of renin-angiotensin system inhibitors in patients with COVID-19.

Г

#### **Mechanical Ventilation**

Of the trials, 9 collected outcome data on need for mechanical ventilation (n=1838; Figure 2D), with 6 trials reporting 185 mechanical ventilation events. There was

no difference in the rate of mechanical ventilation between people on RASi compared with controls (10.1% versus 10.0%; RR, 1.00; [95% CI, 0.76–1.31];  $l^2$ =0%; P=0.99). Analysis comparing trials that commenced

A All-Cause Mortality Study or Subgroup	RAS Events		Conti Events		Weight	Risk Ratio M-H, Fixed 95% Cl	Risk Ratio M-H, Fixed, 95% Cl
ACE-COVID	12	100	8	104	11.3%	1.56 [0.67, 3.66]	
ALPS COVID IP	11	101	9	104	12.8%	1.26 [0.54, 2.91]	<b>_</b>
ARB use to minimize respiratory failure	1	16	1	15	1.5%	0.94 [0.06, 13.7]	
BRACE CORONA	9	325	9	334	12.8%	1.03 [0.41, 2.56]	
COVID MED	2	9	0	3	12.8%	2.00 [0.12, 33.1]	
Evaluation of the effects of losartan in COVID-19		41	5	39	7.4%	0.38 [0.08, 1.85]	
PRAETORIAN-COVID	2	11	1	12	1.4%	2.18 [0.23, 20.8]	
RAAS-COVID	1	25	2	21	3.1%	0.42 [0.04, 4.31]	
REPLACE COVID	11	75	10	77	14.2%	1.13 [0.51, 2.50]	
STAR COVID	8	32	7	32	10.1%	1.14 [0.47, 2.78]	<b>_</b>
SWITCH-COVID	4	10	1	8	1.6%	3.20 [0.44, 23.3]	
Telmisartan for treatment of COVID-19	3	78	16	80	22.8%	0.19 [0.06, 0.63]	
All other trials	0	94	0	92	-	non-estimable	
Total (95% CI)		917		921	100.0%	0.95 [0.69, 1.30]	•
Total events	66		69				
Heterogeneity: $Chi^2$ =13.01, df = 11, (p=0.29); $I^2$ = Test for overall effect Z = 0.34 (p=0.73)						Ö.01	0:1 1 10 10 Favors RASi Favors Control
B Myocardial Infarction	DAG		C			Diale Date	Diale Datia
	RAS Events		Conti Events		Weight	Risk Ratio M-H, Fixed 95% Cl	Risk Ratio M-H, Fixed, 95% Cl
BRACE CORONA	15	325	25	334	85.2%	0.62 [0.33, 1.15]	
RAAS-COVID	0	25	3	21	13.1%	0.12 [0.01, 2.22]	
REPLACE COVID	1	75	0	77	1.7%	3.08 [0.13, 74.4]	
All other trials	0		0		-	non-estimable	
An other thats	U	346	U	343	-	non-estimable	
Total (95% CI)	16	771	20	775	100.0%	0.59 [0.33, 1.06]	•
Total events	16		28			L	
Heterogeneity: Chi <sup>2</sup> =2.19, df = 2, (p=0.33); l <sup>2</sup> =9%						0.01	0,1 1 10 10
Test for overall effect Z = 1.76 (p=0.08)							Favors RASi Favors Control
<b>C</b> Intensive Care Admission	RAS		Contr	rol .		Dick Datio	Dick Datio
			Contr Events		Weight	Risk Ratio M-H, Fixed 95% Cl	Risk Ratio M-H, Fixed, 95% Cl
ACE-COVID	18	100	20	104	22.5%	0.94 [0.53, 1.66]	
ALPS COVID IP	36	101	28	104	31.7%	1.32 [0.88, 2.00]	+ <b>-</b> -
	1	58	1	59			
ALPS COVID OP					1.1%	1.02 [0.07, 15.9]	
ARB use to minimize respiratory failure	1	16	2	15	2.4%	0.47 [0.05, 4.65]	
COVID MED	4	9	0	3	0.8%	3.60 [0.25, 52.6]	
PRAETORIAN-COVID	1	11	2	12	2.2%	0.55 [0.06, 5.21]	
RAAS-COVID	1	25	3	21	3.7%	0.28 [0.03, 2.50]	
REPLACE COVID	16	75	14	77	15.9%	1.17 [0.62, 2.23]	<b>_</b>
SWITCH-COVID	4	10	2	8	2.6%	1.60 [0.39, 6.62]	
Telmisartan for treatment of COVID-19	6	78	15	80	17.0%	0.41 [0.17, 1.00]	
All other trials	0	36	0	33	-	non-estimable	
Total (95% CI)		519		516	100.0%	1.00 [0.77, 1.30]	
Total events	88	515	87	010	10010/0	100[017]100]	Ť
Heterogeneity: Chi <sup>2</sup> =9.18, df = 9, (p=0.42); l <sup>2</sup> =2%						0.01	0.1 1 10 10
Test for overall effect Z = 0.02 (p=0.98)						0.01	Favors RASi Favors Control
D Mechanical Ventilation	RAS		Contr			Risk Ratio	Risk Ratio
Study or Subgroup			Events		-	M-H, Fixed 95% Cl	M-H, Fixed, 95% Cl
	8	100	10	104	10.6%	0.83 [0.34, 2.02]	
		101	17	104	18.1%	1.27 [0.71, 2.27]	
	21			15	1.1%	0.94 [0.06, 13.7]	
ALPS COVID IP	21 1	16	1				
ALPS COVID IP ARB use to minimize respiratory failure		16 325	1 32	334	34.1%	0.80 [0.49, 1.32]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA	1				34.1% 0.8%		
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED	1 25 4	325 9	32	334 3	0.8%	3.60 [0.25, 52.6]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19	1 25 4 8	325 9 41	32 0 9	334 3 39	0.8% 10.0%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID	1 25 4 8 0	325 9 41 11	32 0 9 2	334 3 39 12	0.8% 10.0% 2.6%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID RAAS-COVID	1 25 4 8 0 1	325 9 41 11 25	32 0 9 2 2	334 3 39 12 21	0.8% 10.0% 2.6% 2.3%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07] 0.42 [0.04, 4.31]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID RAAS-COVID REPLACE COVID	1 25 4 8 0 1 10	325 9 41 11 25 75	32 0 9 2 2 8	334 3 39 12 21 77	0.8% 10.0% 2.6% 2.3% 8.5%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07] 0.42 [0.04, 4.31] 1.28 [0.54, 3.07]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID RAAS-COVID REPLACE COVID STAR COVID	1 25 4 8 0 1 10 8	325 9 41 11 25 75 32	32 0 9 2 2 8 6	334 3 39 12 21 77 32	0.8% 10.0% 2.6% 2.3% 8.5% 6.5%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07] 0.42 [0.04, 4.31] 1.28 [0.54, 3.07] 1.33 [0.52, 3.41]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID RAAS-COVID REPLACE COVID STAR COVID	1 25 4 8 0 1 10	325 9 41 11 25 75	32 0 9 2 2 8	334 3 39 12 21 77	0.8% 10.0% 2.6% 2.3% 8.5%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07] 0.42 [0.04, 4.31] 1.28 [0.54, 3.07]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID RAAS-COVID REPLACE COVID STAR COVID SWITCH-COVID	1 25 4 8 0 1 10 8	325 9 41 11 25 75 32	32 0 9 2 2 8 6	334 3 39 12 21 77 32	0.8% 10.0% 2.6% 2.3% 8.5% 6.5%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07] 0.42 [0.04, 4.31] 1.28 [0.54, 3.07] 1.33 [0.52, 3.41]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID RAAS-COVID REPLACE COVID STAR COVID SWITCH-COVID Telmisartan for treatment of COVID-19	1 25 4 8 0 1 10 8 3	325 9 41 11 25 75 32 10	32 0 9 2 2 8 6 1	334 3 12 21 77 32 8	0.8% 10.0% 2.6% 2.3% 8.5% 6.5% 1.2%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07] 0.42 [0.04, 4.31] 1.28 [0.54, 3.07] 1.33 [0.52, 3.41] 2.40 [0.30, 18.9]	
ACE-COVID ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID RAAS-COVID REPLACE COVID STAR COVID STAR COVID Telmisartan for treatment of COVID-19 All other trials Total (95% CI)	1 25 4 8 0 1 10 8 3 4	325 9 41 11 25 75 32 10 78 94	32 0 9 2 2 8 6 1 4	334 3 39 12 21 77 32 8 80 92	0.8% 10.0% 2.6% 2.3% 8.5% 6.5% 1.2% 4.3%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07] 0.42 [0.04, 4.31] 1.28 [0.54, 3.07] 1.33 [0.52, 3.41] 2.40 [0.30, 18.9] 1.03 [0.27, 3.96] non-estimable	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID RAAS-COVID REPLACE COVID STAR COVID SWITCH-COVID Telmisartan for treatment of COVID-19 All other trials <b>Total (95% CI)</b>	1 25 4 8 0 1 10 8 3 4 0	325 9 41 11 25 75 32 10 78	32 0 9 2 2 8 6 1 4 0	334 3 39 12 21 77 32 8 80 92	0.8% 10.0% 2.6% 2.3% 8.5% 6.5% 1.2% 4.3%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07] 0.42 [0.04, 4.31] 1.28 [0.54, 3.07] 1.33 [0.52, 3.41] 2.40 [0.30, 18.9] 1.03 [0.27, 3.96]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID RAAS-COVID REPLACE COVID STAR COVID SWITCH-COVID Telmisartan for treatment of COVID-19 All other trials <b>Total (95% CI)</b> Total events	1 25 4 8 0 1 10 8 3 4 0	325 9 41 11 25 75 32 10 78 94	32 0 9 2 2 8 6 1 4	334 3 39 12 21 77 32 8 80 92	0.8% 10.0% 2.6% 2.3% 8.5% 6.5% 1.2% 4.3%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07] 0.42 [0.04, 4.31] 1.28 [0.54, 3.07] 1.33 [0.52, 3.41] 2.40 [0.30, 18.9] 1.03 [0.27, 3.96] non-estimable 1.00 [0.76, 1.31]	
ALPS COVID IP ARB use to minimize respiratory failure BRACE CORONA COVID MED Evaluation of the effects of losartan in COVID-19 PRAETORIAN-COVID RAAS-COVID REPLACE COVID STAR COVID SWITCH-COVID Telmisartan for treatment of COVID-19 All other trials <b>Total (95% CI)</b>	1 25 4 8 0 1 10 8 3 4 0	325 9 41 11 25 75 32 10 78 94	32 0 9 2 2 8 6 1 4 0	334 3 39 12 21 77 32 8 80 92	0.8% 10.0% 2.6% 2.3% 8.5% 6.5% 1.2% 4.3%	3.60 [0.25, 52.6] 0.85 [0.36, 1.97] 0.22 [0.01, 4.07] 0.42 [0.04, 4.31] 1.28 [0.54, 3.07] 1.33 [0.52, 3.41] 2.40 [0.30, 18.9] 1.03 [0.27, 3.96] non-estimable	

versus those that continued/discontinued RASi also did not demonstrate differences in mechanical ventilation rates (P=0.41 for subgroup differences; Figure S26).

#### Hypotension Requiring Inotropes

A total of 9 trials measured hypotension requiring inotropes (n=1500; Figure 3A), with 6 trials reporting a total of 127 events requiring inotropes. In the total group, there was no increase in inotrope use between people on RASi compared with no RASi (8.6% versus 8.4%; RR, 1.01; [95% Cl, 0.73–1.41]; /<sup>2</sup>=0%; P=0.93). However, sensitivity analyses restricted to patients with severe COVID-19 demonstrated that RASi was associated with a trend to increased risk of hypotension requiring inotropes compared with controls (33.8% versus 20.3%; RR, 1.56; [95% Cl, 0.88-2.79]; l<sup>2</sup>=0%; P=0.13; Figure S27). Analysis comparing trials that commenced RASi showed a nonsignificant increase in inotrope use compared with those that continued/discontinued RASi (RR, 1.40 [95% CI, 0.82-2.39] versus RR, 0.84 [95% CI, 0.55-1.28], respectively; P=0.15 for subgroup comparison; Figure S28).

#### **AKI and Need for Dialysis**

A total of 9 trials measured AKI outcomes (n=887; Figure 3B); 6 trials of hospitalized patients reported 47 AKI events. Increased AKI (7.0% versus 3.6%; RR, 1.82; [95% CI, 1.05–3.16];  $l^2$ =0%; P=0.033) was noted in the RASi versus control groups. Although the AKI events were low, this effect was consistent across trials that initiated RASi versus those that continued/ discontinued RASi (P=0.90 for subgroup differences; Figure S29) and across those with mild, moderate, and severe COVID-19 (P=0.90 for subgroup differences; Figure S30). There was no statistically significant increase in need for dialysis in the RASi group compared with control (2.4% versus 2.1%; RR, 1.15; [95% CI, 0.60–2.21];  $l^2$ =0%; P=0.67; Figure 3C).

### DISCUSSION

In this meta-analysis of 14 clinical trials in patients with COVID-19, we found no effect on all-cause mortality, a trend toward decreased myocardial infarction, and an increased risk of AKI in patients randomly assigned to RASi versus controls. Evidence from RCTs in patient groups without COVID-19 including those with hypertension and high cardiovascular risk has also indicated an increased risk of AKI from RASi-based blood pressure (BP) lowering but decreases in vascular events from RASi therapy long term,<sup>34</sup> suggesting that these effects in patients with COVID-19 may be real. In this analysis, the safety of RASi was seen across other outcomes, including heart failure, stroke,

hospitalization, need for intensive care, and use of inotropes or mechanical ventilation. This is consistent with observational studies that suggested there was no adverse effect of renin-angiotensin system blockade on COVID-19 severity and outcomes.<sup>16,35–38</sup> The totality of data from this international collaboration provides strong evidence to suggest that RASi can be safely used in patients with COVID-19 while being aware of an increased risk of AKI, which will better inform public health policy and clinical decision making.

The collective inclusion of data from >1800 patients enabled us to conduct several subgroup analyses. Consistent effects were seen across subgroups. The majority of patients used RASi therapy for the treatment of hypertension, but results in the subgroups with cardiovascular disease and chronic kidney disease were reassuring. Importantly, we were able to demonstrate for the first time that there was no statistically significant difference in ACEI versus ARB use on all-cause mortality. This suggests that neither the upstream renin-angiotensin syndrome inhibition by ACEIs nor the downstream inhibition at the receptor level by ARBs influence mortality outcomes in COVID-19.

We found an almost 2-fold increased risk of AKI associated with RASi in patients hospitalized with acute COVID-19 in hospitalized patients, with CIs suggesting a minor to a 4-fold increase. This risk is a potentially important finding that was unknown before our metaanalysis.<sup>39</sup> Effects were consistent across trials that initiated and those that continued RASi,<sup>40-42</sup> but were not associated with increased need for dialysis or mortality at short-term follow-up. AKI is common in COVID-19, with proteinuria often seen in those admitted to hospital,<sup>43</sup> although the mechanisms appear to be multicausal. Some studies suggest that SARS-CoV-2 can directly infect the renal tubular epithelium through an ACE2-dependent pathway,<sup>40-42,44</sup> whereas others have instead demonstrated acute tubular necrosis, thrombotic microangiopathy, glomerulonephritis, and other intrinsic renal disease.45-47 Kidney invasion of SARS-CoV-2 has been difficult to demonstrate consistently in all studies, and whether it directly leads to AKI is controversial.<sup>48</sup> There have been reports of virus detected in the kidney by different methods,<sup>49</sup> but others did not find any such evidence.<sup>48</sup> The kidneys may be particularly susceptible to SARS-CoV-2 because of the high ACE2 expression<sup>50,51</sup> and coexpression of the cell surface protease facilitating viral cell entry transmembrane serine protease 2 in the proximal tubular cells and tubular progenitor cells.4,52 AKI in COVID-19 can stem from hypovolemia, hypotension, hypoxia, and inflammation or use of different nephrotoxic medications (eg, nonsteroidal anti-inflammatory drugs) or their combined effects.<sup>53</sup> It is well recognized that RASi produces reduction in intraglomerular pressure and this can translate into a drop in glomerular

#### A Hypotension requiring inotropes

	RAS	i	Conti	ol		<b>Risk Ratio</b>		Risk R	atio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed 95% C	l i	M-H, Fixed	, 95% CI	
ACE-COVID	4	100	8	104	12.5%	0.52 [0.16, 1.67]			_	
ALPS COVID IP	19	101	13	104	20.4%	1.50 [0.79, 2.88]		-	-	
BRACE CORONA	23	325	28	334	43.9%	0.84 [0.50, 1.43]			-	
COVID MED	3	9	0	3	1.1%	2.80 [0.18, 42.8]				
REPLACE COVID	9	75	8	77	12.6%	1.16 [0.47, 2.83]				
STAR COVID	6	32	6	32	9.5%	1.00 [0.36, 2.77]				
All other trials	0	104	0	100	-	non-estimable				
Total (95% CI)		746		754	100.0%	1.01 [0.73, 1.41]				
Total events	64		63				1			
Heterogeneity: Chi <sup>2</sup> =3.75, df = 5, (p=0.59); I <sup>2</sup> =0%							0.01	0.1 1	1'0	100
Test for overall effect Z = 0.09 (p=0.93)								Favors RASi	Favors Control	

### **B** Acute kidney injury

	RAS	i	Contr	ol		Risk Ratio		Risk R	latio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed 95% Cl	l	M-H, Fixed	l, 95% Cl	
ACE-COVID	1	100	0	104	2.8%	3.12 [0.13, 75.7]				
ALPS COVID IP	19	101	11	104	61.7%	1.78 [0.89, 3.55]		-		
COVID MED	1	9	0	3	4.1%	1.20 [0.06, 23.7]			•	
REPLACE COVID	3	75	3	77	16.9%	1.03 [0.21, 4.93]				
STAR COVID	5	32	2	32	11.4%	2.50 [0.52, 11.9]		_		
SWITCH-COVID	2	10	0	8	3.1%	4.09 [0.22, 74.8]				
All other trials	0	119	0	113	-	non-estimable				
Total (95% CI)		446		441	100.0%	1.82 [1.05, 3.16]			•	
Total events	31		16							
Heterogeneity: Chi <sup>2</sup> =1.16, df = 5, (p=0.95); l <sup>2</sup> =0%	6						L		<u>_</u>	
Test for overall effect Z = 2.13 (p=0.03)							0.01	0.1 1	10	100
								Favors RASi	Favors Control	

### <sup>c</sup> Acute kidney injury requiring dialysis

Study or Subgroup	RAS Events		Cont Events		Weight	Risk Ratio M-H, Fixed 95% Cl		Risk R M-H, Fixed		
ACE-COVID	1	100	0	104	3.0%	3.12 [0.13, 75.7]				
ALPS COVID IP	4	101	3	104	18.2%	1.37 [0.32, 5.98]			-	
BRACE CORONA	9	325	11	334	66.6%	0.84 [0.35, 2.00]				
REPLACE COVID	2	75	1	77	6.1%	2.05 [0.19, 12.2]				-
STAR COVID	2	32	1	32	6.1%	2.00 [0.19, 21.0]				
All other trials	0	113	0	103	-	non-estimable				
Total (95% CI)		746		754	100.0%	1.15 [0.60, 2.21]		•		
Total events	18		16					1		
Heterogeneity: Chi <sup>2</sup> =1.37, df = 4, (p=0.85); l <sup>2</sup> =0%							0.01	0.1 1	10	100
Test for overall effect Z = 0.42 (p=0.67)								Favors RASi	Favors Contro	bl

#### Figure 3. Adverse outcomes at short-term follow-up (≤30 days).<sup>7-15</sup>

ACEI-COVID, the stopping ace-inhibitors in COVID-19 trial; ALPS-COVID IP, angiotensin receptor blocker based lung protective strategy for COVID-19 inpatient trial; ALPS-COVID OP, angiotensin receptor blocker based lung protective strategy for COVID-19 outpatient trial; BRACE CORONA, blockers of angiotensin receptor and angiotensin-converting enzyme inhibitors suspension in hospitalized patients with coronavirus infection; COVERAGE-France, randomized trial to evaluate the safety and efficacy of outpatient treatments to reduce the risk of worsening in individuals with COVID-19 with risk factors; COVID MED, comparison of therapeutics for hospitalized patients infected with SARS-CoV-2; M-H indicates Mantel–Haenszel; PRAETORIAN-COVID, randomised clinical trial with valsartan for prevention of acute respiratory distress syndrome in hospitalised patients with SARS-COV-2 infection disease; RAAS-COVID, renin-angiotensin aldosterone system inhibitors in COVID-19 trial; RASi, renin-angiotensin system inhibitors; REPLACE COVID, the randomized elimination or prolongation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in coronavirus disease 2019; STAR-COVID, telmisartan in respiratory failure due to COVID-19; and SWITCH-COVID, switch of renin-angiotensin system inhibitors in patients with COVID-19.

filtration rate,<sup>54</sup> in particular in patients whose baseline kidney function is compromised.<sup>54</sup> Analyses in patients without COVID-19<sup>55,56</sup> have demonstrated that a decline in glomerular filtration rate associated with intensive BP reduction actually preserves blood flow to the renal tubules, a region highly sensitive to hypoxia and susceptible to acute tubular necrosis with

sustained hypoperfusion.<sup>57</sup> Longer term follow-up is needed to investigate clinical outcomes in patients with a history of COVID-19 treated with RASi—previous studies in patients without COVID-19 demonstrated that angiotensin-converting enzyme inhibition or ARBbased treatment is associated with lower mortality in the follow-up after AKI.<sup>58</sup>

We also observed a borderline decrease in acute myocardial infarction with continuation of RASi therapy. The results were driven by the BRACE CORONA trial<sup>7</sup> (RR, 0.66; [95% Cl, 0.33-1.15]), with the addition of 2 smaller trials further confirming this trend in our metaanalysis (RR, 0.59; [95% Cl, 0.33-1.06]; P=0.078). These 3 trials all compared continuation versus discontinuation of RASi therapy in people with preexisting hypertension and/or cardiovascular disease. The result is unsurprising given the well-established benefits afforded by RASi therapy in the reduction in cardiovascular mortality, myocardial infarction, and stroke.59,60 One small RCT (n=46) demonstrated that RASi discontinuation increased the incidence of acute heart failure (33% versus 4%; P=0.016),<sup>15</sup> which was consistent with the direction of effect observed in our analysis. The short duration of this analysis did not allow the longer beneficial effects of RASi to be demonstrated. Increased vascular events have been observed with RASi cessation,<sup>61</sup> with continuation leading to avoidance of drug discontinuation syndromes. The benefits of RASi can take months to accrue, but the risks of withdrawal occur more rapidly.<sup>62</sup> Our results support the importance of continuing RASi in people with elevated cardiovascular risk-including patients with COVID-19-consistent with the recommendations of international guidelines.18-22

There are a number of limitations to the present analysis. Our meta-analysis focused on binary clinical end points, and benefits on continuous outcomes (eg, length of stay, duration of ventilation) were not assessed. Visual inspection of the all-cause mortality funnel plot also suggested an underrepresentation of trials showing benefit with RASi therapy. This is likely to arise from poor recruitment leading to trial termination (NCT04329195), inability to participate in this meta-analysis because of failure to meet predefined recruitment targets for unblinding (NCT04360551, NCT04351581), or provision of only a low number of participants to the analysis (NCT04335786, NCT04328012, NCT04493359). The relatively low event rates and short follow-up duration of included trials (≤30 days) also prevents robust assessment of long-term outcomes. The risk profile of patients included in RCTs may also limit the extrapolation of the results to patient groups in clinical practice who are older and more comorbid. The results also do not evaluate the posological discrimination of the ARBs used in each clinical trial.<sup>63</sup> Further research is required to assess the mechanism of AKI associated with RASi, rates of renal recovery, and the benefits of RASi for the treatment of proteinuria in these patients and other longer term outcomes. Nevertheless, this is the largest pooled analysis of RCTs compared with other metaanalyses that were smaller<sup>64</sup> or included observational studies<sup>65</sup> and represents a major achievement in international collaboration. This is the most highly powered randomized analysis to assess binary clinical end points and the first to directly compare ACEIs versus ARBs.

This first meta-analysis of RCTs evaluating RASi versus control in patients with COVID-19 found no difference in all-cause mortality, a borderline decrease in myocardial infarction, and an increased risk of AKI with RASi. The risk of AKI was consistent across trials that initiated and those that continued RASi. More evidence is needed with longer term follow-up to establish the clinical implications of this finding.

### CONCLUSION

Early controversies that RASi therapy may upregulate the ACE2 receptor and hence pose safety and efficacy issues in patients with COVID-19 has resulted in several RCTs to be conducted across the globe to address this issue. Our meta-analysis including 14 RCTs suggests that RASi can be safely used (continued or initiated) in patients with COVID-19. In those using RASi, we report a trend toward decreased myocardial infarction, with a potential increased risk of AKI-a finding unknown in patients with COVID-19 before our meta-analysis. Our inclusion of several trials also enabled the first direct comparison of ACEIs versus ARBs, but our findings indicate no difference. Overall, this meta-analysis provides strong evidence that RASi can be used safely in patients with COVID-19, balancing both the benefits and risks on cardiovascular and renal outcomes, respectively.

### **ARTICLE INFORMATION**

Received April 8, 2022; Revised June 23, 2022; accepted June 28, 2022.

#### Affiliations

The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia (S.R.G., G.L.D.T., A.R., A.E.S.); Department of Medical and Surgical Sciences, University of Bologna, Italy (C.B.); Department of Cellular and Molecular Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Canada (D.B.); Interdisciplinary Medicine in Cardiology Unit, InCor, University of Sao Paulo, Brazil (B.C.); School of Health and Life Sciences, Federation University Australia, Ballarat, VIC, Australia (F.C.); Division of Cardiovascular Medicine (J.A.C.); and Renal-Electrolyte and Hypertension Division and Department of Biostatistics, Epidemiology, and Informatics (J.B.C.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Department of Cardiology and Hypertension, Hypertension Excellence Center, Hôpital Saint André, Centre Hospitalier Universitaire de Bordeaux & University Bordeaux, Bordeaux, France (A.C.); Department of Infectious Diseases and Tropical Medicine, Division of Tropical Medicine and Clinical International Health, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux & University Bordeaux, Bordeaux, France (A.D.); Bassett Medical Center, Cooperstown, NY (D.F.); Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands (D.H.G., R.R.v.K.); Netherlands Heart Institute, Utrecht, The Netherlands (D.H.G., R.R.v.K.); Departamento de Medicina Interna, Hospital General, Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social, Mexico City, Mexico (A.E.G.); Departamento de Medicina Interna, Hospital Regional de Alta Especialidad de Zumpango, Estado de Mexico, Mexico (A.E.G.); Division of Biostatistics, School of Public Health, University of Minnesota,

Minneapolis, MN (T.A.M.); Asociacion Argentina de Medicamentos, Ciudad Autonoma de Buenos Aires, Argentina (F.P., R.R.); Servicio de Anatomía Patologica, Hospital de Alta Complejidad El Calafate SAMIC, Santa Cruz, Argentina (F.P.); Imperial Clinical Trials Unit, Imperial College London, London, UK (N.R.P.); Department of Emergency Medicine Hennepin County Medical Center, University of Minnesota, Minneapolis, MN (M.A.P.); Medizinische Klinik und Poliklinik I, Ludwig Maximilian University Hospital Munich, Munich, Germany (K.D.R.); Sociedad Argentina de Farmacología Clínica, Asociacion Medica Argentina, Buenos Aires, Argentina (R.R.); Dobney Hypertension Centre, Medical School, Royal Perth Hospital Unit-Royal Perth Hospital Medical Research Foundation, University of Western Australia, Perth, Australia (M.P.S.); Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria (M.S.); Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada (A.S.); Hypertension Center STRIDE-7, School of Medicine, Third Department of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece (G.S.S.); Department of Surgery, University of Minnesota, Minneapolis, MN (C.J.T.); Division of Cardiovascular Sciences, Faculty of Medicine, Biology and Health, University of Manchester, Manchester, UK (M.T.); Manchester Academic Health Science Centre, Manchester University National Health Service Foundation Trust Manchester, Manchester, UK (M.T.); Cardiovascular Research Institute Maastricht-School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands (T.U.); Department of Pharmacology and Experimental Therapeutics and the Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA (R.D.W.); and Institute of Cardiovascular Science, University College London and National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (B.W.).

#### Acknowledgments

We thank Stella Galanis, Medical Librarian.

#### Sources of Funding

None.

#### Disclosures

Dr Gnanenthiran is supported by a postdoctoral fellowship from the Heart Foundation of Australia. Dr Chirinos has recently consulted for Bayer, Sanifit, Fukuda-Denshi, Bristol-Myers Squibb, JNJ, Edwards Life Sciences, Merck, NGM Biopharmaceuticals, and the Galway-Mayo Institute of Technology. He received University of Pennsylvania research grants from National Institutes of Health, Fukuda-Denshi, Bristol-Myers Squibb, Microsoft, and Abbott. He is named as inventor in a University of Pennsylvania patent for the use of inorganic nitrates/nitrites for the treatment of heart failure and preserved ejection fraction and for the use of biomarkers in heart failure with preserved ejection fraction. He has received payments for editorial roles from the American Heart Association, the American College of Cardiology, and Wiley. He has received research device loans from Atcor Medical, Fukuda-Denshi, Uscom, NDD Medical Technologies, Microsoft, and MicroVision Medical. Dr Schutte received consultancy fees from Abbott and speaker honoraria from Servier, Sanofi, Sun Pharmaceuticals, Omron, Takeda, and Novartis. Dr Stergiou received consultancy fees and speaker honoraria from Astra-Zeneca, Menarini, Novartis, Sanofi, and Servier. Dr Schlaich has received consulting fees and/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer, and Boehringer-Ingelheim. Dr Sharma reports receiving support from the Fonds de Recherche Santé Quebec Junior 1 clinician scholar program, Canada Institute for Health Research (grant 175095), Roche Diagnostics, Boeringer-Ingelheim, Novartis, and Takeda. Dr Poulter has received financial support from several pharmaceutical companies that manufacture blood pressure-lowering agents, for consultancy fees (Servier), research projects and staff (Servier, Pfizer), and for arranging and speaking at educational meetings (AstraZeneca, Lri Therapharma, Napi, Servier, Sanofi, Eva Pharma, Pfizer, Alkem Laboratories, and Glenmark Pharma). He holds no stocks or shares in any such companies. Dr Williams has received honoraria for lectures on hypertension from Servier, Menarini, Pfizer, Boehringer Ingelheim, and Daiichi Sankyo. The remaining authors have no disclosures to report.

#### **Supplemental Material**

Data S1 Tables S1–S2 Figures S1–S30

#### REFERENCES

- Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. *Circulation*. 2012;126:2105–2114. doi: 10.1161/ CIRCULATIONAHA.112.096156
- Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensinconverting enzyme 2. *Circulation*. 2005;111:2605–2610. doi: 10.1161/ CIRCULATIONAHA.104.510461
- Ocaranza MP, Moya J, Barrientos V, Alzamora R, Hevia D, Morales C, Pinto M, Escudero N, García L, Novoa U, et al. Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. *J Hypertens*. 2014;32:771–783. doi: 10.1097/HJH.00000000000094
- Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell.* 2020;181:271–280.e8. doi: 10.1016/j.cell.2020.02.052
- Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. *Hypertension*. 2020;75:1382– 1385. doi: 10.1161/HYPERTENSIONAHA.120.15082
- Wysocki J, Lores E, Ye M, Soler MJ, Batlle D. Kidney and lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19. *J Am Soc Nephrol.* 2020;31:1941–1943. doi: 10.1681/ASN.2020050667
- Lopes RD, Macedo A, de Barros E, Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, Feldman A, D'Andréa Saba Arruda G, de Albuquerque DC, et al. Effect of discontinuing vs continuing angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325:254–264. doi: 10.1001/jama.2020.25864
- Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, Rodriguez-Mori JE, Renna N, Chang TI, Corrales-Medina V, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. *Lancet Respir Med*. 2021;9:275–284. doi: 10.1016/S2213-2600(20)30558-0
- Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, Weiss G, Bellmann-Weiler R, Adolf C, Wolf D, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. *Lancet Respir Med.* 2021;9:863–872. doi: 10.1016/ S2213-2600(21)00214-9
- Duarte M, Pelorosso F, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A, Azzato F, Castro M, Coyle J, Davolos I, et al. Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial. *EClinicalMedicine*. 2021;37:100962. doi: 10.1016/j. eclinm.2021.100962
- Geriak M, Haddad F, Kullar R, Greenwood KL, Habib M, Habib C, Willms D, Sakoulas G. Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized COVID-19 patients with mild hypoxemia. *Infect Dis Ther.* 2021;10:1323–1330. doi: 10.1007/s40121-021-00453-3
- Nouri-Vaskeh M, Kalami N, Zand R, Soroureddin Z, Varshochi M, Ansarin K, Rezaee H, Taghizadieh A, Sadeghi A, Ahangari Maleki M, et al. Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: a randomised clinical trial. *Int J Clin Pract*. 2021;75:e14124. doi: 10.1111/ijcp.14124
- Puskarich MA, Cummins NW, Ingraham NE, Wacker DA, Reilkoff RA, Driver BE, Biros MH, Bellolio F, Chipman JG, Nelson AC, et al. A multicenter phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. *EClinicalMedicine*. 2021;37:100957. doi: 10.1016/j.eclinm.2021.100957
- Puskarich MA, Ingraham NE, Merck LH, Driver BE, Wacker DA, Page Black L, Jones AE, Fletcher CV, South AM, Nelson AC, et al. Effect of losartan on hospitalized patients with COVID-19-induced lung injury: a randomized clinical trial. *JAMA Netw Open*. 2022;5:e222735. doi: 10.1001/jamanetworkopen.2022.2735
- 15. Sharma A, Elharram M, Afilalo J, Flannery A, Afilalo M, Tselios C, Ni J, Ezekowitz JA, Cheng MP, Ambrosy AP, et al. A randomized controlled

trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. *Am Heart J.* 2022;247:76–89. doi: 10.1016/j.ahj.2022.01.015

- de Abajo FJ, Rodriguez-Martin S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Laredo L, Laosa O, Centeno-Soto GA, Ángeles Gálvez M, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. *Lancet*. 2020;395:1705–1714. doi: 10.1016/S0140-6736(20)31030-8
- Jiang X, Eales J, Scannali D, Nazgiewicz A, Prestes P, Maier M, Denniff M, Xu X, Saluja S, Cano-Gamez E, et al. Hypertension and reninangiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney. *Eur Heart J.* 2020;41:4580–4588. doi: 10.1093/eurheartj/ehaa794
- International Society of Hypertension. Statement on COVID-19. 2020. Available at: https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19. Accessed May 6, 2020.
- American College of Cardiology, American Heart Association and Heart Failure Society of America. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician 2020. Available at: https://www.acc.org/latest-in-cardiology/ articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-conce rns-re-using-raas-antagonists-in-covid-19. Accessed May 6, 2020.
- European Society of Cardiology Council on Hypertension. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers 2020. Available at: https://www.escar dio.org/Councils/Council-on-Hypertension-(CHT)/News/position-state ment-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed May 6, 2020.
- 21. European Society of Hypertension. Statement on COVID-19 2020. Available at: https://www.eshonline.org/spotlights/esh-stabtement -on-covid-19. Accessed May 6, 2020.
- The Renal Association. UK position statement on COVID-19 and ACE Inhibitor/Angiotensin Receptor Blocker use. 2020. Available at: https:// renal.org/covid-19/ra-resources-renal-professionals/renal-associatio n-uk-position-statement-covid-19-ace-inhibitorangiotensin-receptorblocker-use. Accessed Oct 6, 2020.
- Liberati A, Altman DF, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;21:b2700. doi: 10.1136/bmj.b2700
- Gnanenthiran SR, Borghi C, Burger D, Charchar F, Poulter NR, Schlaich MP, Steckelings UM, Stergiou G, Tomaszewski M, Unger T, et al. Prospective meta-analysis protocol on randomised trials of reninangiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension. *BMJ Open*. 2021;11:e043625. doi: 10.1136/bmjopen-2020-043625
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). 2019.
- Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–c184. doi: 10.1159/000339789
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:I4898. doi: 10.1136/bmj.I4898
- Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis. *Psychol Methods*. 1998;3:486–504. doi: 10.1007/978-1-0716-1566-9\_3
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629
- Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med.* 2004;23:1351–1375. doi: 10.1002/sim.1761
- Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. *BMC Med Res Methodol*. 2015;15:58. doi: 10.1186/s12874-015-0060-8
- Rucker G. Network meta-analysis, electrical networks and graph theory. *Res Synth Methods*. 2012;3:312–324. doi: 10.1002/jrsm.1058
- ClinicalTrials.gov. Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (COVERAGE France). 2021.
- 34. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary

prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. *Lancet*. 2021;397:1625–1636. doi: 10.1016/S0140-6736(21)00590-0

- Jung SY, Choi JC, You SH, Kim WY. Association of renin-angiotensinaldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study. *Clin Infect Dis.* 2020;71(16):2121–2128. doi: 10.1093/cid/ciaa624
- Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5:825–830. doi: 10.1001/ jamacardio.2020.1624
- Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Reninangiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431–2440. doi: 10.1056/NEJMoa2006923
- Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, et al. Reninangiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441–2448. doi: 10.1056/NEJMoa2008975
- Nadim MK, Forni LG, Mehta RL, Connor MJ Jr, Liu KD, Ostermann M, Rimmelé T, Zarbock A, Bell S, Bihorac A, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. *Nat Rev Nephrol.* 2020;16:747–764. doi: 10.1038/s41581-020-00356-5
- Larsen CP, Bourne TD, Wilson JD, Saqqa O, Sharshir MA. Collapsing glomerulopathy in a patient with coronavirus disease 2019 (COVID-19). *Kidney Int Rep.* 2020;5:935–939. doi: 10.1016/j.ekir.2020.04.002
- Su H, Yang M, Wan C. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney Int.* 2020;98:219–227. doi: 10.1016/j.kint.2020.04.006
- Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. *Lancet Respir Med*. 2020;7(7):738–742. doi: 10.1016/S2213-2600(20)30229-0
- Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Am Soc Nephrol. 2020;31:1157–1165. doi: 10.1681/ASN.2020030276
- Braun F, Lutgehetmann M, Pfefferle S, Wong MN, Carsten A, Lindenmeyer MT, Nörz D, Heinrich F, Meißner K, Wichmann D, et al. SARS-CoV-2 renal tropism associates with acute kidney injury. *Lancet*. 2020;396:597–598. doi: 10.1016/S0140-6736(20)31759-1
- May RM, Cassol C, Hannoudi A, Larsen CP, Lerma EV, Haun RS, Braga JR, Hassen SI, Wilson J, VanBeek C, et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). *Kidney Int*. 2021;100:1303–1315. doi: 10.1016/j.kint.2021.07.015
- Akilesh S, Nast CC, Yamashita M, Henriksen K, Charu V, Troxell ML, Kambham N, Bracamonte E, Houghton D, Ahmed NI, et al. Multicenter clinicopathologic correlation of kidney biopsies performed in COVID-19 patients presenting with acute kidney injury or proteinuria. *Am J Kidney Dis*. 2021;77(1):82–93. doi: 10.1053/j.ajkd.2020.10.001
- Sharma P, Uppal NN, Wanchoo R, Shah HH, Yang Y, Parikh R, Khanin Y, Madireddy V, Larsen CP, Jhaveri KD, et al. COVID-19-associated kidney injury: a case series of kidney biopsy findings. *Clin J Am Soc Nephrol.* 2020;31:1948–1958. doi: 10.1681/ASN.2020050699
- Hassler L, Reyes F, Sparks MA, Welling P, Batlle D. Evidence for and against direct kidney infection by SARS-CoV-2 in patients with COVID-19. *Clin J Am Soc Nephrol.* 2021;16:1755–1765. doi: 10.2215/CJN.04560421
- Garreta E, Prado P, Stanifer ML, Monteil V, Marco A, Ullate-Agote A, Moya-Rull D, Vilas-Zornoza A, Tarantino C, Romero JP, et al. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells. *Cell Metab.* 2022;34:857–873.e9. doi: 10.1016/j.cmet.2022.04.009
- Li MY, Lin L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infect Dis Poverty*. 2020;9:45. doi: 10.1186/s40249-020-00662-x
- Ye M, Wysocki J, William J, Soler MJ, Cokic I, Battle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17:3067–3075. doi: 10.1681/ ASN.2006050423
- Pan XW, Xu D, Zhang H, Zhou W, Wang LH, Cui XG. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. *Intensive Care Med.* 2020;46:1114–1116. doi: 10.1007/s00134-020-06026-1

- Legrand M, Bell S, Forni L, Joannidis M, Koyner JL, Liu K, Cantaluppi V. Pathophysiology of COVID-19-associated acute kidney injury. *Nat Rev Nephrol.* 2021;1–14(11):751–764.
- Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern? *Arch Intern Med.* 2000;160:685–693. doi: 10.1001/archinte.160.5.685
- Nadkarni GN, Chauhan K, Rao V, Ix JH, Shlipak MG, Parikh CR, Coca SG. Effect of intensive blood pressure lowering on kidney tubule injury: findings from the ACCORD trial study participants. *Am J Kidney Dis*. 2019;73:31–38. doi: 10.1053/j.ajkd.2018.07.016
- Malhotra R, Craven T, Ambrosius WT, Killeen AA, Haley WE, Cheung AK, Chonchol M, Sarnak M, Parikh CR, Shlipak MG, et al. Effects of intensive blood pressure lowering on kidney tubule Injury in CKD: a longitudinal subgroup analysis in SPRINT. *Am J Kidney Dis.* 2019;73:21–30. doi: 10.1053/j.ajkd.2018.07.015
- Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, Wiesener MS, Willam C. Role of hypoxia in the pathogenesis of renal disease. *Kidney Int Suppl.* 2005;99:S46–S51. doi: 10.1111/j.1523-1755.2005.09909.x
- Brar S, Ye F, James MT, Hemmelgarn B, Klarenbach S, Pannu N, Interdisciplinary Chronic Diseases Collaboration. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury. *JAMA Intern Med.* 2018;178:1681–1690. doi: 10.1001/jamainternmed.2018.4749
- Heart Outcomes Prevention Evaluation Study Investigators, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153. doi: 10.1056/NEJM200001203420301

- Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016;387:957–967. doi: 10.1016/ S0140-6736(15)01225-8
- Hirakawa Y, Arima H, Webster R, Zoungas S, Li Q, Harrap S, Lisheng L, Hamet P, Mancia G, Poulter N, et al. Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes. *J Hypertens*. 2016;34:781–787. doi: 10.1097/ HJH.000000000000841
- Alharbi FF, Souverein P, de Groot MC, Maitland-van der Zee AH, de Boer A, Klungel OH. Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study. *J Hum Hypertens*. 2017;31:537–544. doi: 10.1038/jhh.2017.1
- Rothlin RP, Duarte M, Pelorosso FG, Nicolosi L, Salgado MV, Vetulli HM, Spitzer E. Angiotensin receptor blockers for COVID-19: pathophysiological and pharmacological considerations about ongoing and future prospective clinical trials. *Front Pharmacol.* 2021;12:603736. doi: 10.3389/ fphar.2021.603736
- Kow CS, Ming LC, Hasan SS. Renin-angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a metaanalysis of randomized controlled trials. *Hypertens Res.* 2021;44:1042– 1045. doi: 10.1038/s41440-021-00670-w
- Bavishi C, Whelton PK, Mancia G, Corrao G, Messerli FH. Reninangiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. J Hypertens. 2021;39:784–794. doi: 10.1097/ HJH.000000000002784

# SUPPLEMENTAL MATERIAL

# Data S1. Trials that contributed grouped tabular data

Trial Name	Trial Team
ACEI-COVID	Team: Bauer A, Sappler N, Dolejsi T, Tilg H, Aulinger BA, Weiss G, Bellmann-Weiler R, Adolf C, Wolf D, Pirklbauer M, Graziadei I, Gänzer H, von Bary C, May AE, Wöll E, von Scheidt W, Rassaf T, Duerschmied D, Brenner C, Kääb S, Metzler B, Joannidis M, Kain HU, Kaiser N, Schwinger R, Witzenbichler B, Alber H, Straube F, Hartmann N, Achenbach S, von Bergwelt-Baildon M, von Stülpnagel L, Schoenherr S, Forer L, Embacher-Aichhorn S, Mansmann U, Massberg S Funding: Austrian Science Fund and German Center for Cardiovascular Research.
RAAS-COVID	Team: Elharram M, Ni J, Afilalo J, Flannery A, Ezekowitz JA, Cheng MP, Ambrosy AP, Zannad F, Brophy J, Giannetti N, Bessissow A, Kronfli N, Marelli A. Aziz H, Alqahtani M, Aflaki M, Craig M, Lopes RD, Ferreira JP Funding: McGill Interdisciplinary Initiative in Infection and Immunity (MI4) and the Division of Cardiology at McGill University.
REPLACE- COVID	Team: Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, Rodriguez-Mori JE, Renna N, Chang TI, Corrales-Medina V, Andrade-Villanueva JF, Barbagelata A, Cristodulo- Cortez R, Díaz-Cucho OA, Spaak J, Alfonso CE, Valdivia-Vega R, Villavicencio-Carranza M, Ayala-García RJ, Castro-Callirgos CA, González-Hernández LA, Bernales-Salas EF, Coacalla- Guerra JC, Salinas-Herrera CD, Nicolosi L, Basconcel M, Byrd JB, Sharkoski T, Bendezú- Huasasquiche LE, Chittams J, Edmonston DL, Vasquez CR Funding: REPLACE COVID Investigators, REPLACE COVID Trial Social Fundraising Campaign, and FastGrants.
SWITCH- COVID	Team: Girardi ACC, Tavares CAM, Cardozo FAM, Betonico GN, de Almeida L Funding: University of Sao Paulo
ALPS-COVID IP	Team: Ingraham NE, Merck LH, Driver BE, Wacker DA, Black LP, Jones AE, Fletcher CV, South AM, Nelson AC, Lewandowski C, Farhat J, Benoit JL, Biros MH, Cherabuddi K, Chipman JG, Schacker TW, Guirgis FW, Voelker HT, Koopmeiners JS, Tignanelli CJ Funding: Bill and Melinda Gates Foundation, NIH
ALPS-COVID OP	Team: Cummins NW, Ingraham NE, Wacker DA, Reilkoff RA, Driver BE, Biros MH, Bellolio F, Chipman JG, Nelson AC, Beckman K, Langlois R, Bold T, Aliota MT, Schacker TW, Voelker HT, Koopmeiners JS Funding: Minnesota Partnership for Biotechnology and Medical Genomics
COVERAGE- France	Team: Malvy D, Anglaret X, Richert L, Wittkop L, Lhomme E, Sitta R, Gelley A, Hardel L, Wallet C, Schwimmer C, Thiebaut R, Onaisi R, Saint-Lary O, Joseph JP, Dupouy J, Gimenez L, Boucaut A, Chastang J, Naccache JM, Piroth L, Binquet C, Lefèvre B, Makinson A, Picot MC, Montoya A, Crantelle L, Molimard M, Bouchet S, de Lamballerie X, Roussillon C, Landman R Funding: Ministère des Solidarités et de la Santé, Agence Nationale de la Recherche, ANRS   Maladies Infectieuses Emergentes, University of Bordeaux
COVID MED	Team: Victory J, Jenkins P, Krupa N, Wheeler J, Vail GM, Riesenfeld E, Cross P, Gilmore C, Huckabone M, Schworm A, Boregowda U, Deshmukh F, Choi Y, Khan A, Gadomski A Funding: Bassett Healthcare, Reid Health, Goshen Health System
PRAETORIAN- COVID	Team: Aarts GWA, Konijnenberg LSF, Mensink FB, Herrmann JJ. Funding: NLHI, the Dutch Heart Foundation, Novartis Pharma and ZonMW grant 10430012010020
STAR-COVID	Team: Ángeles-Duran GY, Flores-Gómez IR, Flores-Martínez E, Valdin-Orozco TI, Pedraza- Hervert C Funding: National Polytechnic Institute, Mexico
Telmisartan for treatment of patients with COVID-19	Team: Duarte M, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A, Azzato F, Castro M, Coyle J, Davolos I, Criado IF, Gregori R, Mastrodonato P, Rubio MC, Sarquis S, Wahlmann F Funding: Facultad de Medicina (Universidad de Buenos Aires, Argentina), Hospital Espa~nol de Buenos Aires (Argentina) and Laboratorio Elea (Argentina)

 Table S1. Quality assessment of RCTs – Cochrane Collaboration Risk of Bias Tool.

Trial Name	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and researchers (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other
ACEI-COVID	Low risk	High risk	High risk	Low risk	Low risk	Low risk	Open label trial
BRACE-CORONA	Low risk	High risk	High risk	Low risk	Low risk	Low risk	Open label trial
RAAS-COVID	Low risk	High risk	High risk	Unclear risk	Low risk	Low risk	Open label trial
REPLACE-COVID	Low risk	High risk	High risk	Low risk	Low risk	Low risk	Open label trial
SWITCH-COVID	Low risk	High risk	High risk	Low risk	Low risk	Low risk	Open label trial
ALPS-COVID IP	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Placebo controlled
ALPS-COVID OP	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Placebo controlled
ARB use to minimize progression to respiratory failure	Low risk	High risk	High risk	Unclear risk	Low risk	Low risk	Open label trial
COVERAGE-France	Low risk	High risk	High risk	Low risk	Low risk	Low risk	Open label trial
COVID MED	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Placebo controlled
Evaluation of the effect of losartan in COVID-19	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Comparator amlodipine rather than placebo
PRAETORIAN-COVID	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Placebo controlled
STAR-COVID	Low risk	High risk	High risk	Low risk	Low risk	Low risk	Open label trial
Telmisartan for treatment of patients with COVID- 19	Low risk	High risk	High risk	Unclear risk	High risk	Unclear risk	Open label trial loss to follow- up:>10%

	Original analyses RR, 95%CI	Sensitivity analyses* RR, 95%CI
Mortality	RR 0.95 (0.69-1.30), p=0.73	RR 0.95 (0.69-1.30), p=0.73
Myocardial infarction	RR 0.59 (0.33-1.06), p=0.08	RR 0.60 (0.24-1.06), p=0.08
Intensive care admission	RR 1.00 (0.77-1.30), p=0.98	RR 1.02 (0.78-1.32), p=0.90
Mechanical ventilation	RR 1.00 (0.76-1.31), p=0.99	RR 1.02 (0.77-1.35), p=0.90
Hypotension requiring inotropes	RR 1.01 (0.73-1.41), p=0.93	RR 1.01 (0.73-1.41), p=0.93
Acute kidney injury	RR 1.82 (1.05-3.16), p=0.03	RR 1.82 (1.05-3.14), p=0.03
Acute kidney injury requiring dialysis	RR 1.15 (0.60-2.21), p=0.67	RR 1.15 (0.60-2.19), p=0.68

### Table S2. Sensitivity analyses to account for small counts in trials\*

RR relative risk, CI confidence interval

\*Sensitivity analysis using the reciprocal of the sample size of the opposite arm to the cells in tables with zeroes

# Figure S1. Quality assessment of RCTs – Cochrane Collaboration Risk of Bias Tool.

	RASI	Control	Risk of Bias	
Study or Subgroup	Total	Total	ABCDEFG	_
ACE-COVID	100	104		
ALPS COVID IP	101	104	$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$	
ALPS-COVID OP	58	59	$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$	Disk of king language
ARB use to minimize respiratory failure	16	15		Risk of bias legend
BRACE CORONA	325	334		(A) Random sequence generation (selection bias)
COVERAGE France	36	33		(B) Allocation concealment (selection bias)
COVID MED	9	3	$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$	(C) Blinding of participants and personnel (performance bias)
Evaluation of the effects of losartan in COVID-19	41	39	$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$	( <b>D</b> ) Blinding of outcome assessment (detection bias)
PRAETORIAN-COVID	11	12	$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$	(E) Incomplete outcome data (attrition bias)
RAAS-COVID	25	21		(F) Selective reporting (reporting bias)
REPLACE COVID	75	77	$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$	(G) Other bias
STAR-COVID	32	32		
SWITCH-COVID	10	8	$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$	
Telmisartan for treatment of COVID-19	78	80	••• • •	
	917	921		

# Figure S2: All-Cause Mortality – Start vs Continue/Discontinue Trials

	RAS	51	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	:	M-H, Fixed, 95% Cl
Start								
ALPS COVID IP	11	101	9	104	12.8%	1.26 [0.54, 2.91]		
ARB use to minimize respiratory failure	1	16	1	15	1.5%	0.94 [0.06, 13.68]		
COVID MED	2	9	0	3	1.0%	2.00 [0.12, 33.10]		
Evaluation of the effects of losartan in COVID-19	2	41	5	39	7.4%	0.38 [0.08, 1.85]		
PRAETORIAN-COVID	2	11	1	12	1.4%	2.18 [0.23, 20.84]		
STAR-COVID	8	32	7	32	10.1%	1.14 [0.47, 2.78]		
Telmisartan for treatment of COVID-19	3	78	16	80	22.8%	0.19 [0.06, 0.63]		
All other trials	0	94	0	92		-		
Subtotal (95% CI)		382		377	56.9%	0.72 [0.46, 1.14]		•
Total events	29		39					-
Heterogeneity: Chi <sup>2</sup> = 9.52, df = 6 (P = 0.15); $I^2$ = 37 Test for overall effect: Z = 1.39 (P = 0.16)	70							
Continue/Discontinue								
ACE-COVID	12	100	8	104	11.3%	1.56 [0.67, 3.66]		
BRACE CORONA	9	325	9	334	12.8%	1.03 [0.41, 2.56]		
RAAS-COVID	1	25	2	21	3.1%	0.42 [0.04, 4.31]		
REPLACE COVID	11	75	10	77	14.2%	1.13 [0.51, 2.50]		
SWITCH-COVID	4	10	1	8	1.6%	3.20 [0.44, 23.28]		
Subtotal (95% CI)		535		544	43.1%	1.24 [0.78, 1.96]		<b>•</b>
Total events	37		30					
Heterogeneity: Chi <sup>2</sup> = 2.20, df = 4 (P = 0.70); I <sup>2</sup> = 0%	, 0							
Test for overall effect: $Z = 0.91$ (P = 0.36)								
Total (95% CI)		917		921	100.0%	0.95 [0.69, 1.30]		
Total events	66		69			_		
Heterogeneity: Chi <sup>2</sup> = 13.01, df = 11 (P = 0.29); l <sup>2</sup> =	15%						H	
Test for overall effect: $Z = 0.34$ (P = 0.73)							0.01	0.1 1 10 1 Favours RASI Favours control
Toot for subgroup differences: $Chi^2 = 2.64$ df = 1 /P	- 0.00)	12 - 540	4					Favours RASI Favours control

Test for subgroup differences:  $Chi^2 = 2.64$ , df = 1 (P = 0.28),  $I^2 = 51\%$ 

# Figure S3: All-Cause Mortality – Placebo Control vs Open Label Trials

	RAS	1	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% CI
Placebo control trials								
ALPS COVID IP	11	101	9	104	13.8%	1.26 [0.54, 2.91]		
COVID MED	2	9	0	3	1.1%	2.00 [0.12, 33.10]		
PRAETORIAN-COVID	2	11	1	12	1.5%	2.18 [0.23, 20.84]		
ALPS-COVID OP	0	58	0	59		-		
Subtotal (95% CI)		179		178	16.4%	1.39 [0.66, 2.96]		-
Total events	15		10					
Heterogeneity: $Chi^2 = 0.27$ , $df = 2$ (P = 0.	.87); l <sup>2</sup> = 0 <sup>6</sup>	%						
Test for overall effect: Z = 0.86 (P = 0.39	)							
Open label								
ACE-COVID	12	100	8	104	12.2%	1.56 [0.67, 3.66]		<b></b>
ARB use to minimize respiratory failure	1	16	1	15	1.6%	0.94 [0.06, 13.68]		
BRACE CORONA	9	325	9	334	13.8%	1.03 [0.41, 2.56]		
RAAS-COVID	1	25	2	21	3.4%	0.42 [0.04, 4.31]		
REPLACE COVID	11	75	10	77	15.4%	1.13 [0.51, 2.50]		
STAR-COVID	8	32	7	32	10.9%	1.14 [0.47, 2.78]		
SWITCH-COVID	4	10	1	8	1.7%	3.20 [0.44, 23.28]		
Telmisartan for treatment of COVID-19	3	78	16	80	24.6%	0.19 [0.06, 0.63]		
COVERAGE France	0	36	0	33		-		
Subtotal (95% CI)		697		704	83.6%	0.91 [0.63, 1.32]		+
Total events	49		54					
Heterogeneity: Chi <sup>2</sup> = 10.62, df = 7 (P = 0	0.16); I <sup>2</sup> = 3	34%						
Test for overall effect: Z = 0.49 (P = 0.62	2)							
Total (95% CI)		876		882	100.0%	0.99 [0.71, 1.38]		•
Total events	64		64			_		
Heterogeneity: Chi <sup>2</sup> = 11.44, df = 10 (P =	: 0.32); l <sup>2</sup> =	13%						
Test for overall effect: Z = 0.06 (P = 0.96	i)						0.01	0.1 1 10 1 Favours RASI Favours control
Test for subgroup differences: Chi <sup>2</sup> = 0.9	8, df = 1 (F	P = 0.32	2), $I^2 = 0\%$	)				Favours RASI Favours control

# Figure S4: All-Cause Mortality – Trial Location

# (A) Random Effect

	RAS		Contr			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
North America							
ALPS COVID IP	11	101	9	104	15.0%	1.26 [0.54, 2.91]	
ALPS-COVID OP	12	100	8	104	14.7%	1.56 [0.67, 3.66]	
ARB use to minimize respiratory failure	1	16	1	15	2.1%	0.94 [0.06, 13.68]	
COVID MED	2	9	0	3	2.0%	2.00 [0.12, 33.10]	
RAAS-COVID	1	25	2	21	2.8%	0.42 [0.04, 4.31]	
STAR-COVID Subtotal (95% CI)	8	32 283	7	32 279	13.9% <b>50.5%</b>	1.14 [0.47, 2.78] 1.26 [0.78, 2.01]	•
Total events	35		27			. / .	•
Heterogeneity: Tau² = 0.00; Chi² = 1.29, df = 5 (P =		= 0%					
Test for overall effect: Z = 0.95 (P = 0.34)							
South America							
BRACE CORONA	9	325	9	334	13.4%	1.03 [0.41, 2.56]	
SWITCH-COVID	4	10	1	8	3.8%	3.20 [0.44, 23.28]	
Telmisartan for treatment of COVID-19	3	78	16	80	9.0%	0.19 [0.06, 0.63]	
Subtotal (95% CI)		413		422	26.2%	0.75 [0.18, 3.21]	
Total events	16		26				
Heterogeneity: Tau <sup>2</sup> = 1.17; Chi <sup>2</sup> = 7.54, df = 2 (P =	0.02); l <sup>2</sup>	= 73%					
Test for overall effect: Z = 0.39 (P = 0.70)							
Europe							
ACE-COVID	12	100	8	104	14.7%	1.56 [0.67, 3.66]	
PRAETORIAN-COVID	2	11	1	12	3.0%	2.18 [0.23, 20.84]	
COVERAGE France	0	36	0	33		-	-
Subtotal (95% CI)		147		149	17.7%	1.63 [0.73, 3.61]	
Total events	14		9				
Heterogeneity: Tau² = 0.00; Chi² = 0.07, df = 1 (P = Test for overall effect: Z = 1.20 (P = 0.23)	0.79); l²	= 0%					
Middle-East							
Evaluation of the effects of losartan in COVID-19	2	41	5	39	5.6%	0.38 [0.08, 1.85]	
Subtotal (95% CI)		41		39	5.6%	0.38 [0.08, 1.85]	
Total events	2		5				
Heterogeneity: Not applicable							
Test for overall effect: Z = 1.20 (P = 0.23)							
Total (95% CI)		884		889	100.0%	1.04 [0.70, 1.56]	+
Total events	67		67				
Heterogeneity: Tau² = 0.10; Chi² = 13.84, df = 11 (F	<sup>o</sup> = 0.24);	l² = 21°	%				1 1 1 10 10
Test for overall effect: Z = 0.19 (P = 0.85)							0.01 0.1 1 10 10 Favours RASI Favours control
	P = 0.39).						

# (B) Fixed Effects

	RAS		Contr			Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI	
North America								
ALPS COVID IP	11	101	9	104	13.2%	1.26 [0.54, 2.91]		
ALPS-COVID OP	12	100	8	104	11.6%	1.56 [0.67, 3.66]	<b>+-</b>	
ARB use to minimize respiratory failure	1	16	1	15	1.5%	0.94 [0.06, 13.68]		
COVID MED	2	9	0	3	1.1%	2.00 [0.12, 33.10]		
RAAS-COVID	1	25	2	21	3.2%	0.42 [0.04, 4.31]		
REPLACE COVID	11	75	10	77		Not estimable		
STAR-COVID	8	32	7	32	10.4%	1.14 [0.47, 2.78]	<b>_</b>	
Subtotal (95% CI)		283		279	41.0%	1.26 [0.79, 2.00]	<b>•</b>	
Total events	35		27					
Heterogeneity: Chi <sup>2</sup> = 1.29, df = 5 (P = 0.94); l <sup>2</sup> = 0%								
Test for overall effect: $Z = 0.96$ (P = 0.34)	•							
South America								
BRACE CORONA	9	325	9	334	13.2%	1.03 [0.41, 2.56]		
SWITCH-COVID	4	10	1	8	1.6%	3.20 [0.44, 23.28]		
Telmisartan for treatment of COVID-19	3	78	16	80	23.5%	0.19 [0.06, 0.63]	<b>_</b>	
Subtotal (95% CI)	-	413		422	38.3%	0.61 [0.33, 1.12]	-	
Total events	16		26					
Heterogeneity: Chi <sup>2</sup> = 7.54, df = 2 (P = 0.02); l <sup>2</sup> = 73 Test for overall effect: Z = 1.59 (P = 0.11)	%							
Europe								
ACE-COVID	12	100	8	104	11.6%	1.56 [0.67, 3.66]		
PRAETORIAN-COVID	2	11	1	12	1.4%	2.18 [0.23. 20.84]		
COVERAGE France	0	36	0	33		-		
Subtotal (95% CI)		147		149	13.1%	1.63 [0.73, 3.61]		
Total events	14		9					
Heterogeneity: Chi <sup>2</sup> = 0.07, df = 1 (P = 0.79); l <sup>2</sup> = 0% Test for overall effect: Z = 1.20 (P = 0.23)	0							
Middle-East								
Evaluation of the effects of losartan in COVID-19 Subtotal (95% CI)	2	41 41	5	39 39	7.6% 7.6%	0.38 [0.08, 1.85] 0.38 [0.08, 1.85]		
Total events	2	41	5	29	1.0%	0.30 [0.00, 1.85]		
Heterogeneity: Not applicable	2		5					
Test for overall effect: $Z = 1.20$ (P = 0.23)								
Total (95% CI)		884		889	100.0%	0.99 [0.72, 1.37]		
Total events	67		67					
Heterogeneity: Chi <sup>2</sup> = 13.84, df = 11 (P = 0.24); $I^2$ =			51				+ + + +	
Test for overall effect: $Z = 0.06$ (P = 0.95)							0.01 0.1 1 10	1(
Test for subgroup differences: $Chi^2 = 6.33$ , $df = 3$ (P							Favours RASI Favours control	

# Figure S5: All-Cause Mortality – Severity of COVID-19

	RAS		Contr			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% Cl
Mild			_				
REPLACE COVID	6	38	5	42	9.1%	1.33 [0.44, 4.00]	
Telmisartan for treatment of COVID-19	1	23	3	25	5.5%	0.36 [0.04, 3.24]	
All other trials	1	66	0	68		-	
Subtotal (95% CI)		127		135	14.6%	0.96 [0.37, 2.50]	
Total events	8		8				T
Heterogeneity: $Chi^2 = 1.09$ , df = 1 (P = 0.1)	30); l² = 8	%					
Test for overall effect: Z = 0.08 (P = 0.94)	)						
Moderate							
ACE-COVID	12	100	8	104	15.0%	1.56 [0.67, 3.66]	
ALPS COVID IP	6	79	4	83	7.5%	1.58 [0.46, 5.38]	
PRAETORIAN-COVID	2	11	1	12	1.8%	2.18 [0.23, 20.84]	
REPLACE COVID	2	28	1	25	2.0%	1.79 [0.17, 18.52]	
SWITCH-COVID	4	10	1	7	2.2%	2.80 [0.39, 20.02]	
Telmisartan for treatment of COVID-19	2	47	13	46	25.1%	0.15 [0.04, 0.63]	
All other trials	0	4	0	3		-	
Subtotal (95% CI)		279		280	53.6%	0.98 [0.60, 1.63]	<b>•</b>
Total events	28		28				
Heterogeneity: $Chi^2 = 10.10$ , df = 5 (P = 0	0.07); l <sup>2</sup> = :	51%					
Test for overall effect: Z = 0.06 (P = 0.95)	)						
Severe							
ALPS COVID IP	5	22	5	21	9.8%	0.95 [0.32, 2.83]	-+
COVID MED	1	5	0	1	1.4%	1.00 [0.06, 15.99]	
REPLACE COVID	3	9	4	10	7.2%	0.83 [0.25, 2.76]	
STAR-COVID	8	32	7	32	13.4%	1.14 [0.47, 2.78]	
Subtotal (95% CI)		68		64	31.8%	1.01 [0.56, 1.81]	$\bullet$
Total events	17		16				
Heterogeneity: $Chi^2 = 0.18$ , df = 3 (P = 0.18)		%					
Test for overall effect: Z = 0.03 (P = 0.98)	)						
Total (95% CI)		474		479	100.0%	0.99 [0.69, 1.41]	<b></b>
Total events	53		52				
Heterogeneity: Chi <sup>2</sup> = 11.35, df = 11 (P =	0.41); l² =	: 3%					0.01 0.1 1 10 1
Test for overall effect: Z = 0.06 (P = 0.95)							Favours RASI Favours control
Test for subgroup differences: Chi <sup>2</sup> = 0.0	1, df = 2 (F	P = 1.00	D), I <sup>2</sup> = 0%	, D			

## Figure S6: All-Cause Mortality by Angiotensin II type 1 Receptor Blocker

## (A) Random Effects


	RAS	I	Contr	ol		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	1	M-H, Random, 95% Cl	
Losartan									
ALPS COVID IP	11	101	9	104	25.8%	1.26 [0.54, 2.91]			
ARB use to minimize respiratory failure	1	16	1	15	5.6%	0.94 [0.06, 13.68]			
COVID MED	2	9	0	3	5.2%	2.00 [0.12, 33.10]			
Evaluation of the effects of losartan in COVID-19	2	41	5	39	12.9%	0.38 [0.08, 1.85]			
ALPS-COVID OP	0	58	0	59					
Subtotal (95% CI)		225		220	49.5%	1.01 [0.51, 2.02]		<b></b>	
Total events	16		15						
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.97, df = 3 (P = Test for overall effect: Z = 0.03 (P = 0.98)	: 0.58); l² =	= 0%							
Telmisartan									
COVERAGE France	0	36	0	33		-			
STAR-COVID	8	32	7	32	24.6%	1.14 [0.47, 2.78]			
Telmisartan for treatment of COVID-19	3	78	16	80	18.4%	0.19 [0.06, 0.63]			
Subtotal (95% CI)		146		145	43.0%	0.49 [0.08, 2.97]			
Total events	11		23						
Heterogeneity: Tau <sup>2</sup> = 1.41; Chi <sup>2</sup> = 5.89, df = 1 (P = Test for overall effect: Z = 0.78 (P = 0.44)	: 0.02); l² =	= 83%							
Valsartan									
PRAETORIAN-COVID	2	11	1	12	7.5%	2.18 [0.23, 20.84]			
Subtotal (95% CI)		11		12	7.5%	2.18 [0.23, 20.84]			
Total events	2		1						
Heterogeneity: Not applicable									
Test for overall effect: Z = 0.68 (P = 0.50)									
Total (95% CI)		382		377	100.0%	0.78 [0.40, 1.54]		•	
Total events	29		39						
Heterogeneity: Tau <sup>2</sup> = 0.28; Chi <sup>2</sup> = 9.52, df = 6 (P =	0.15); l <sup>2</sup> =	= 37%							
Test for overall effect: Z = 0.71 (P = 0.48)	,,						0.01	0.1 1 10 Favours RASI Favours control	100
Test for subgroup differences: $Chi^2 = 1.06$ , df = 2 (F	P = 0.59),	l² = 0%						Favours RASI Favours control	

## (B) Fixed Effects

	RAS	1	Contr	ol		<b>Risk Ratio</b>		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	1	M-H, Fixed, 95% Cl
Losartan								
ALPS COVID IP	11	101	9	104	22.5%	1.26 [0.54, 2.91]		
ARB use to minimize respiratory failure	1	16	1	15	2.6%	0.94 [0.06, 13.68]		
COVID MED	2	9	0	3	1.8%	2.00 [0.12, 33.10]		
Evaluation of the effects of losartan in COVID-19	2	41	5	39	13.0%	0.38 [0.08, 1.85]		
ALPS-COVID OP	0	58	0	59		-		
Subtotal (95% CI)		225		220	39.9%	0.99 [0.50, 1.93]		<b>•</b>
Total events	16		15					
Heterogeneity: Chi <sup>2</sup> = 1.97, df = 3 (P = 0.58); I <sup>2</sup> = 0%								
Test for overall effect: Z = 0.04 (P = 0.97)								
Telmisartan								
STAR-COVID	8	32	7	32	17.7%	1.14 [0.47, 2.78]		
Telmisartan for treatment of COVID-19	3	78	16	80	40.0%	0.19 [0.06, 0.63]		<b>_</b>
COVERAGE France	0	36	0	33		-		
Subtotal (95% CI)		146		145	57.7%	0.48 [0.25, 0.94]		$\bullet$
Total events	11		23					
Heterogeneity: Chi <sup>2</sup> = 5.89, df = 1 (P = 0.02); l <sup>2</sup> = 83%	6							
Test for overall effect: Z = 2.13 (P = 0.03)								
Valsartan								
PRAETORIAN-COVID	2	11	1	12	2.4%	2.18 [0.23, 20.84]		
Subtotal (95% CI)		11		12	2.4%	2.18 [0.23, 20.84]		
Total events	2		1					
Heterogeneity: Not applicable								
Test for overall effect: Z = 0.68 (P = 0.50)								
Total (95% CI)		382		377	100.0%	0.72 [0.46, 1.14]		•
Total events	29		39					
Heterogeneity: Chi <sup>2</sup> = 9.52, df = 6 (P = 0.15); l <sup>2</sup> = 37%							<u> </u>	
Test for overall effect: $Z = 1.39$ (P = 0.16)	-						0.01	0.1 1 10 100 Favours RASI Favours control
Test for subgroup differences: $Chi^2 = 3.12$ , df = 2 (P =	= 0.21).	l <sup>2</sup> = 55.	9%					Favours KASI Favours control

### Figure S7: Publication bias and all-cause mortality

(A) Observed trials; (B) Observed and imputed trials.



Open circles: observed trials; closed black circles: imputed trials

# Figure S8: All-Cause Mortality – Age subgroups

	RAS		Contr			Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI	
<60 years								
ALPS COVID IP	2	62	2	59	4.0%	0.95 [0.14, 6.54]		
COVID MED	1	3	0	1	1.3%	1.50 [0.10, 22.62]		
REPLACE COVID	4	31	1	33	1.9%	4.26 [0.50, 36.04]		_
STAR-COVID	6	25	6	27	11.1%	1.08 [0.40, 2.91]		
SWITCH-COVID	3	6	1	3	2.6%	1.50 [0.25, 8.98]		
All other trials	0	100	0	103		-		
Subtotal (95% CI)		227		226	20.8%	1.42 [0.70, 2.87]	-	
Total events	16		10					
Heterogeneity: $Chi^2 = 1.48$ , $df = 4$ (P = 0 Test for overall effect: Z = 0.97 (P = 0.33)	,,	%						
≥60 years								
ACE-COVID	12	89	8	83	16.0%	1.40 [0.60, 3.25]		
ALPS COVID IP	9	39	7	45	12.5%	1.48 [0.61, 3.61]	_ <b>-</b>	
COVID MED	1	6	0	2	1.3%	1.29 [0.07, 23.39]		
PRAETORIAN-COVID	2	3	1	5	1.4%	3.33 [0.49, 22.90]		
REPLACE COVID	7	44	9	44	17.4%	0.78 [0.32, 1.90]	<b>_</b>	
STAR-COVID	2	7	1	5	2.2%	1.43 [0.17, 11.76]		
SWITCH-COVID	1	4	0	5	0.9%	3.60 [0.18, 70.34]		
Telmisartan for treatment of COVID-19	3	44	16	55	27.4%	0.23 [0.07, 0.75]	<b>_</b>	
All other trials	0	39	0	33		-		
Subtotal (95% CI)		275		277	79.2%	0.93 [0.62, 1.40]	★	
Total events	37		42					
Heterogeneity: $Chi^2 = 10.15$ , $df = 7$ (P = Test for overall effect: Z = 0.34 (P = 0.73)		31%						
Total (95% CI)		502		503	100.0%	1.03 [0.73, 1.47]	•	
Total events	53		52			, ,	Ţ	
Heterogeneity: Chi <sup>2</sup> = 11.87, df = 12 (P =		0%	52				F F F	
Test for overall effect: $Z = 0.18$ (P = 0.86	<i>,</i> ,	0,0					0.01 0.1 1 10	10
Test for subgroup differences: $Chi^2 = 1.0$	/	- 0 3 <sup>,</sup>	1) 12 - 27	70/_			Favours RASI Favours control	

# Figure S9: All-Cause Mortality – Sex

	RAS		Contr			Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% CI	
Male									
ACE-COVID	11	64	5	65	9.5%	2.23 [0.82, 6.07]		+	
ALPS COVID IP	6	60	8	63	14.9%	0.79 [0.29, 2.14]			
COVID MED	1	6	0	2	1.3%	1.29 [0.07, 23.39]			-
PRAETORIAN-COVID	1	5	1	12	1.1%	2.40 [0.18, 31.29]			
REPLACE COVID	7	42	7	42	13.3%	1.00 [0.38, 2.60]		<b>_</b>	
STAR-COVID	6	19	5	21	9.1%	1.33 [0.48, 3.65]		<del></del>	
SWITCH-COVID	2	7	0	4	1.2%	3.13 [0.19, 52.60]			
Telmisartan for treatment of COVID-19	2	43	6	29	13.7%	0.22 [0.05, 1.04]			
All other trials	0	39	0	48		-			
Subtotal (95% CI)		285		286	64.0%	1.08 [0.70, 1.66]		<b>•</b>	
Total events	36		32						
Heterogeneity: Chi <sup>2</sup> = 7.57, df = 7 (P = 0.	37); l <sup>2</sup> = 8	%							
Test for overall effect: Z = 0.36 (P = 0.72	)								
Female									
ACE-COVID	1	36	3	39	5.5%	0.36 [0.04, 3.32]	-		
ALPS COVID IP	5	41	1	41	1.9%	5.00 [0.61, 40.95]			
COVID MED	1	3	0	1	1.3%	1.50 [0.10, 22.62]			-
PRAETORIAN-COVID	1	6	0	4	1.1%	2.14 [0.11, 42.52]			
REPLACE COVID	4	33	3	35	5.5%	1.41 [0.34, 5.85]		<del></del>	
STAR-COVID	2	13	2	11	4.1%	0.85 [0.14, 5.06]			
SWITCH-COVID	2	3	1	4	1.6%	2.67 [0.41, 17.42]			
Telmisartan for treatment of COVID-19	1	27	10	42	14.9%	0.16 [0.02, 1.15]			
All other trials	0	55	0	44		-			
Subtotal (95% CI)		217		221	36.0%	0.94 [0.50, 1.75]		•	
Total events	17		20		/0			Ţ	
Heterogeneity: $Chi^2 = 8.18$ , df = 7 (P = 0.		4%	20						
Test for overall effect: $Z = 0.20$ (P = 0.84									
Total (95% CI)		502		507	100.0%	1.03 [0.72, 1.47]		•	
Total events	53		52					Ť	
Heterogeneity: Chi <sup>2</sup> = 15.66, df = 15 (P =		- 1%	52				<b>—</b>		
Test for overall effect: $Z = 0.17$ (P = 0.86		+ /0					0.01	0.1 1 10	1
Test for subgroup differences: $Chi^2 = 0.17$	/							Favours RASI Favours contro	

# Figure S10: All-Cause Mortality – Ethnicity

tudy or Subgroup Vhite CE-COVID	Events	i otal	Events	Lotal	weight	M-H, Fixed, 95% C	
				Total	morgine	M-11, 1 1XCu, 3370 0	I M-H, Fixed, 95% CI
CE-COVID	12	100	8	104	21.8%	1.56 [0.67, 3.66]	
LPS COVID IP	4	35	7	47	16.6%	0.77 [0.24, 2.42]	
OVID MED	2	9	0	3	2.0%	2.00 [0.12, 33.10]	
RAETORIAN-COVID	2	10	1	12	2.5%	2.40 [0.25, 22.75]	
EPLACE COVID	2	30	1	31	2.7%	2.07 [0.20, 21.61]	
WITCH-COVID	3	7	0	6	1.5%	6.13 [0.38, 99.14]	
Il other trials	0	45	0	39		-	
ubtotal (95% CI)		236		242	47.1%	1.52 [0.85, 2.72]	•
otal events	25		17				-
eterogeneity: Chi <sup>2</sup> = 2.59, df = 5 (P = 0 est for overall effect: Z = 1.40 (P = 0.10		6					
outh-East/East Asian							
EPLACE COVID	0	1	1	3	2.8%	0.67 [0.04, 10.05]	
Il other trials	0	7	0	2	2.0,0	-	
ubtotal (95% CI)		8		5	2.8%	0.67 [0.04, 10.05]	
otal events	0	Ŭ	1	Ũ	,		
leterogeneity: Not applicable est for overall effect: Z = 0.29 (P = 0.7)							
frican							
EPLACE COVID	1	10	0	13	1.2%	3.82 [0.17, 84.90]	
WITCH-COVID	1	3	1	2	3.3%	0.67 [0.08, 5.54]	
Il other trials	0	5	0	4	0.070	-	
ubtotal (95% CI)		18		19	4.6%	1.51 [0.28, 8.07]	
otal events	2		1			• • •	-
leterogeneity: Chi <sup>2</sup> = 0.92, df = 1 (P = 0 est for overall effect: Z = 0.48 (P = 0.63	0.34); l <sup>2</sup> = 0%	6					
Other							
LPS COVID IP	2	22	1	25	2.6%	2.27 [0.22, 23.38]	
EPLACE COVID	8	34	8	30	23.6%	0.88 [0.38, 2.06]	
TAR-COVID	8	32	7	32	19.4%	1.14 [0.47, 2.78]	
Il other trials	0	8	0	11		-	
ubtotal (95% CI)		96		98	45.6%	1.07 [0.59, 1.93]	+
otal events leterogeneity: Chi² = 0.62, df = 2 (P = 0 est for overall effect: Z = 0.23 (P = 0.82		6	16				
otal (95% CI)		358		364	100.0%	1.29 [0.87, 1.92]	•
otal events	45		35				
eterogeneity: Chi <sup>2</sup> = 4.86, df = 11 (P =	$0.94$ ); $I^2 = 0$	1%					0.01 0.1 1 10
est for overall effect: Z = 1.26 (P = 0.2							0.01 0.1 1 10 Favours RASI Favours control

Test for subgroup differences:  $\dot{Chi}^2 = 0.93$ , df = 3 (P = 0.82), l<sup>2</sup> = 0%

## Figure S11: All-Cause Mortality – COPD vs no COPD

### (A) Random Effects

	RAS	61	Contr	rol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	l	M-H, Random, 95% Cl
COPD								
ACE-COVID	5	22	0	10	4.3%	5.26 [0.32, 86.90]		
ALPS COVID IP	8	10	3	65	10.1%	17.33 [5.50, 54.62]		
REPLACE COVID	3	9	3	17	9.0%	1.89 [0.47, 7.52]		
SWITCH-COVID	1	1	1	1	10.2%	1.00 [0.32, 3.10]		
Telmisartan for treatment of COVID-19	0	6	1	8	3.9%	0.43 [0.02, 9.00]		
All other trials	0	8	0	3		-		
Subtotal (95% CI)		56		104	37.5%	2.68 [0.65, 11.02]		
Total events	17		8					
Heterogeneity: Tau <sup>2</sup> = 1.73; Chi <sup>2</sup> = 14.97	', df = 4 (P	= 0.00	5); l² = 73	%				
Test for overall effect: Z = 1.37 (P = 0.17	')							
No COPD								
ACE-COVID	7	78	8	94	10.9%	1.05 [0.40, 2.78]		
ALPS COVID IP	3	89	6	89	9.1%	0.50 [0.13, 1.94]		
COVID MED	1	2	0	2	4.4%	3.00 [0.19, 47.96]		
PRAETORIAN-COVID	2	11	1	11	5.7%	2.00 [0.21, 18.98]		
REPLACE COVID	8	66	7	80	11.0%	1.39 [0.53, 3.62]		
STAR-COVID	8	32	7	32	11.3%	1.14 [0.47, 2.78]		
Telmisartan for treatment of COVID-19	3	64	15	63	9.9%	0.20 [0.06, 0.65]		
All other trials	0	101	0	98		-		
Subtotal (95% CI)		443		469	62.5%	0.86 [0.47, 1.56]		-
Total events	32		44					
Heterogeneity: Tau <sup>2</sup> = 0.23; Chi <sup>2</sup> = 9.57,	df = 6 (P =	= 0.14);	l² = 37%					
Test for overall effect: Z = 0.50 (P = 0.62	?)							
Total (95% CI)		499		573	100.0%	1.36 [0.67, 2.75]		•
Total events	49		52					
Heterogeneity: Tau <sup>2</sup> = 0.94; Chi <sup>2</sup> = 34.28	s, df = 11 (l	P = 0.00	003); I <sup>2</sup> =	68%				
Test for overall effect: Z = 0.85 (P = 0.40	))						0.01	0.1 1 10 10 Favours RASI Favours control
Test for subgroup differences: $Chi^2 = 2.1$	2 df = 1 (I	P = 0.14	5) $l^2 = 52$	8%				Favours RASI Favours control

Test for subgroup differences:  $Chi^2 = 2.12$ , df = 1 (P = 0.15), l<sup>2</sup> = 52.8%

### (B) Fixed Effects

	RAS	1	Contr	ol		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-H, Fix	ed, 95% Cl	
COPD										
ACE-COVID	5	22	0	10	1.4%	5.26 [0.32, 86.90]			· · · ·	
ALPS COVID IP	8	10	3	65	1.6%	17.33 [5.50, 54.62]				
REPLACE COVID	3	9	3	17	4.2%	1.89 [0.47, 7.52]			<u>├ • ─ </u>	
SWITCH-COVID	1	1	1	1	3.0%	1.00 [0.32, 3.10]			+	
Telmisartan for treatment of COVID-19	0	6	1	8	2.6%	0.43 [0.02, 9.00]			<u> </u>	
All other trials	0	8	0	3		-				
Subtotal (95% CI)		56		104	12.8%	3.68 [1.96, 6.89]			•	
Total events	17		8							
Heterogeneity: Chi <sup>2</sup> = 14.97, df = 4 (P = 1	0.005); l² =	73%								
Test for overall effect: Z = 4.06 (P < 0.00	01)									
No COPD										
ACE-COVID	7	78	8	94	14.6%	1.05 [0.40, 2.78]			<u>+</u>	
ALPS COVID IP	3	89	6	89	12.1%	0.50 [0.13, 1.94]			+	
COVID MED	1	2	0	2	1.0%	3.00 [0.19, 47.96]			<u> </u>	
PRAETORIAN-COVID	2	11	1	11	2.0%	2.00 [0.21, 18.98]			+ • · · · · · · · · · · · · · · · · · ·	
REPLACE COVID	8	66	7	80	12.8%	1.39 [0.53, 3.62]		_	+	
STAR-COVID	8	32	7	32	14.1%	1.14 [0.47, 2.78]			<b> </b>	
Telmisartan for treatment of COVID-19	3	64	15	63	30.5%	0.20 [0.06, 0.65]				
All other trials	0	101	0	98		-		_		
Subtotal (95% CI)		443		469	87.2%	0.78 [0.51, 1.20]		•		
Total events	32		44							
Heterogeneity: $Chi^2 = 9.57$ , df = 6 (P = 0	.14); I <sup>2</sup> = 3	7%								
Test for overall effect: Z = 1.13 (P = 0.26	)									
Total (95% CI)		499		573	100.0%	1.16 [0.83, 1.62]			•	
Total events	49		52							
Heterogeneity: Chi <sup>2</sup> = 34.28, df = 11 (P =	: 0.0003); I	² = 68%	6					0.1	1 10	10
Test for overall effect: Z = 0.85 (P = 0.40	)						0.01		1 10 Favours contro	10

Test for subgroup differences:  $Chi^2 = 16.02$ , df = 1 (P < 0.0001),  $l^2 = 93.8\%$ 

# Figure S12: All-Cause Mortality – Hypertension vs no Hypertension

	RAS	1	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% Cl
Hypertension								
ACE-COVID	12	99	8	100	15.5%	1.52 [0.65, 3.55]		<b></b>
ALPS COVID IP	6	35	6	46	10.1%	1.31 [0.46, 3.73]		<b>-</b>
PRAETORIAN-COVID	0	2	1	6	1.8%	0.78 [0.04, 14.15]		
REPLACE COVID	11	75	10	77	19.3%	1.13 [0.51, 2.50]		
SWITCH-COVID	4	10	1	8	2.2%	3.20 [0.44, 23.28]		
Telmisartan for treatment of COVID-19	1	30	11	35	19.8%	0.11 [0.01, 0.77]	-	
All other trials	0	17	0	7		-		
Subtotal (95% CI)		268		279	68.7%	1.00 [0.65, 1.56]		•
Total events	34		37					
Heterogeneity: $Chi^2 = 7.49$ , df = 5 (P = 0.	19); l <sup>2</sup> = 3	3%						
Test for overall effect: Z = 0.02 (P = 0.98	)							
No Hypertension								
ALPS COVID IP	5	65	3	58	6.2%	1.49 [0.37, 5.95]		
PRAETORIAN-COVID	2	9	0	6	1.1%	3.50 [0.20, 62.27]		
STAR-COVID	8	29	7	29	13.7%	1.14 [0.48, 2.74]		
Telmisartan for treatment of COVID-19	2	40	5	36	10.3%	0.36 [0.07, 1.74]		
All other trials	0	9	0	15		-		
Subtotal (95% CI)		204		200	31.3%	1.04 [0.55, 1.96]		•
Total events	17		15					T
Heterogeneity: $Chi^2 = 2.72$ , $df = 3$ (P = 0. Test for overall effect: Z = 0.12 (P = 0.90	44); l <sup>2</sup> = 0	%	10					
Total (95% CI)		472		479	100.0%	1.02 [0.71, 1.46]		•
Total events	51		52					
Heterogeneity: Chi <sup>2</sup> = 10.16, df = 9 (P = 0	0.34); l² =	11%					0.01 0.1	
Test for overall effect: Z = 0.09 (P = 0.93	)							1 10 10 burs RASI Favours control
Test for subgroup differences: Chi <sup>2</sup> = 0.0	1, df = 1 (F	= 0.93	3), I <sup>2</sup> = 0%	, D			ravo	Tavours control

# Figure S13: All-Cause Mortality – Diabetes Mellitus vs no Diabetes

	RAS		Contr			Risk Ratio			k Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fi	xed, 95% C		
Diabetes Mellitus											
ACE-COVID	6	37	1	30	2.1%	4.86 [0.62, 38.23]		-	· · ·		
ALPS COVID IP	2	19	2	25	3.2%	1.32 [0.20, 8.51]			-	_	
PRAETORIAN-COVID	1	1	1	3	1.9%	2.00 [0.45, 8.94]				_	
REPLACE COVID	5	42	6	37	11.9%	0.73 [0.24, 2.21]			<b>-</b>		
STAR-COVID	2	9	2	7	4.2%	0.78 [0.14, 4.23]					
SWITCH-COVID	3	7	0	3	1.2%	3.50 [0.23, 52.56]					-
Telmisartan for treatment of COVID-19	0	12	4	14	7.8%	0.13 [0.01, 2.16]		•	<u> </u>		
All other trials	0	8	0	6		-					
Subtotal (95% CI)		135		125	32.4%	1.09 [0.60, 2.01]		•	◆		
Total events	19		16								
Heterogeneity: Chi <sup>2</sup> = 6.25, df = 6 (P = 0.	.40); l <sup>2</sup> = 4	%									
Test for overall effect: Z = 0.29 (P = 0.77	)										
No Diabetes											
ACE-COVID	6	63	7	74	12.1%	1.01 [0.36, 2.84]			<b>-</b>		
ALPS COVID IP	9	80	7	77	13.4%	1.24 [0.48, 3.16]		_			
COVID MED	2	7	0	2	1.4%	1.88 [0.12, 28.78]			+ · · · ·		
PRAETORIAN-COVID	1	10	0	9	1.0%	2.73 [0.12, 59.57]			- · ·		—
REPLACE COVID	6	33	4	40	6.8%	1.82 [0.56, 5.91]		-	<u> </u>		
STAR-COVID	6	23	5	25	9.0%	1.30 [0.46, 3.70]			<b>-</b>		
SWITCH-COVID	1	3	1	5	1.4%	1.67 [0.16, 17.89]					
Felmisartan for treatment of COVID-19	3	58	12	57	22.7%	0.25 [0.07, 0.82]			-		
All other trials	0	88	0	87		-					
Subtotal (95% CI)		365		376	67.6%	0.97 [0.63, 1.50]		•	•		
Total events	34		36			•					
Heterogeneity: Chi <sup>2</sup> = 7.45, df = 7 (P = 0.	.38); l <sup>2</sup> = 6	%									
Test for overall effect: Z = 0.12 (P = 0.91											
Гоtal (95% CI)		500		501	100.0%	1.01 [0.71, 1.44]			♦		
Fotal events	53		52								
Heterogeneity: Chi <sup>2</sup> = 13.74, df = 14 (P =		: 0%					<b>—</b>		-	+	
Test for overall effect: $Z = 0.07$ (P = 0.94							0.01	0.1	1	10	10
Test for subgroup differences: $Chi^2 = 0.0$	,		3) $ ^2 = 0\%$					Favours RAS	a Favours	control	

# Figure S14: All-Cause Mortality – Obesity vs No Obesity

	RAS		Contr			Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl	
Obesity									
ACE-COVID	1	22	4	36	6.2%	0.41 [0.05, 3.43]			
ALPS COVID IP	8	65	3	65	6.2%	2.67 [0.74, 9.61]		+	
COVID MED	1	3	0	2	1.2%	2.25 [0.13, 38.09]			-
REPLACE COVID	5	36	4	37	8.1%	1.28 [0.37, 4.40]		<b>-</b>	
STAR-COVID	0	9	3	11	6.5%	0.17 [0.01, 2.94]			
SWITCH-COVID	1	3	0	2	1.2%	2.25 [0.13, 38.09]			-
Telmisartan for treatment of COVID-19	0	14	2	8	6.4%	0.12 [0.01, 2.23]			
All other trials	0	35	0	30		-			
Subtotal (95% CI)		187		191	35.8%	1.02 [0.54, 1.91]		<b>•</b>	
Total events	16		16						
Heterogeneity: Chi² = 7.18, df = 6 (P = 0. Test for overall effect: Z = 0.07 (P = 0.95		6%							
No Obesity									
ACE-COVID	11	77	4	68	8.7%	2.43 [0.81, 7.27]		+	
ALPS COVID IP	3	38	6	38	12.3%	0.50 [0.13, 1.85]			
COVID MED	1	6	0	1	1.6%	0.86 [0.05, 13.93]			
PRAETORIAN-COVID	2	6	1	8	1.8%	2.67 [0.31, 23.00]			
REPLACE COVID	3	23	1	25	2.0%	3.26 [0.36, 29.17]			
STAR-COVID	8	23	4	21	8.6%	1.83 [0.64, 5.19]			
SWITCH-COVID	3	7	1	6	2.2%	2.57 [0.35, 18.68]			
Telmisartan for treatment of COVID-19	3	56	14	63	27.1%	0.24 [0.07, 0.80]			
All other trials	0	64	0	66		-			
Subtotal (95% CI)		300		296	64.2%	1.05 [0.67, 1.67]		<b>•</b>	
Total events	34		31						
Heterogeneity: Chi <sup>2</sup> = 12.93, df = 7 (P = 0 Test for overall effect: Z = 0.23 (P = 0.82		46%							
Total (95% CI)		487		487	100.0%	1.04 [0.72, 1.51]			
Total events	50		47					[	
Heterogeneity: $Chi^2 = 20.10$ , df = 14 (P =		: 30%					H		
Test for overall effect: $Z = 0.22$ (P = 0.83		0070					0.01	0.1 1 10	1
Test for subgroup differences: $Chi^2 = 0.0$								Favours RASI Favours control	

# Figure S15: All-Cause Mortality – CVD vs no CVD

	RAS	1	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	1	M-H, Fixed, 95% Cl
CVD								
ACE-COVID	7	30	2	32	4.9%	3.73 [0.84, 16.57]		
ALPS COVID IP	1	4	4	9	6.2%	0.56 [0.09, 3.57]		
COVID MED	1	2	0	2	1.3%	3.00 [0.19, 47.96]		
PRAETORIAN-COVID	1	3	0	5	1.0%	4.50 [0.24, 85.12]		
REPLACE COVID	1	10	2	14	4.2%	0.70 [0.07, 6.70]		
Telmisartan for treatment of COVID-19	2	6	4	8	8.7%	0.67 [0.18, 2.51]		
Subtotal (95% CI)		55		70	26.3%	1.48 [0.73, 2.98]		<b>•</b>
Total events	13		12					
Heterogeneity: $Chi^2 = 5.14$ , df = 5 (P = 0. Test for overall effect: Z = 1.09 (P = 0.27)		%						
No CVD								
ACE-COVID	5	70	6	72	11.5%	0.86 [0.27, 2.68]		
ALPS COVID IP	10	97	5	95	9.8%	1.96 [0.70, 5.52]		
COVID MED	1	7	0	1	1.6%	0.75 [0.05, 12.34]	-	
PRAETORIAN-COVID	1	8	1	7	2.1%	0.88 [0.07, 11.54]		
REPLACE COVID	10	65	8	63	15.8%	1.21 [0.51, 2.87]		
STAR-COVID	8	32	7	32	13.6%	1.14 [0.47, 2.78]		
SWITCH-COVID	4	10	1	8	2.2%	3.20 [0.44, 23.28]		
Telmisartan for treatment of COVID-19	1	64	12	63	23.5%	0.08 [0.01, 0.61]		
All other trials	0	58	0	59		-		
Subtotal (95% CI)		411		400	79.8%	0.94 [0.63, 1.43]		<b></b>
Fotal events	40		40					
Heterogeneity: $Chi^2 = 9.59$ , df = 7 (P = 0. Test for overall effect: Z = 0.27 (P = 0.79)		7%						
Total (95% CI)		466		470	100.0%	1.05 [0.74, 1.50]		
Total events	53		52					
Heterogeneity: Chi <sup>2</sup> = 14.40, df = 13 (P =	0.35); l <sup>2</sup> =	10%						0.1 1 10 1
Test for overall effect: Z = 0.28 (P = 0.78)	)						0.01	
Test for subgroup differences: $C = 0.28$ ( $P = 0.78$ ) Test for subgroup differences: $Chi^2 = 1.1$		P = 0.28	3), I² = 14	.3%				Favours RASI Favours control


# Figure S16: All-Cause Mortality – CKD vs no CKD

	RAS	I	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-H, Fixed, 95% CI
CKD								
ACE-COVID	4	21	3	16	6.6%	1.02 [0.26, 3.91]		
REPLACE COVID	1	12	1	17	1.6%	1.42 [0.10, 20.49]		
All other trials	0	4	0	2		-		
Subtotal (95% CI)		37		35	8.2%	1.09 [0.33, 3.64]		
Total events	5		4					
Heterogeneity: $Chi^2 = 0.05$ , df = 1 (P = 0.	,	%						
Test for overall effect: Z = 0.15 (P = 0.88	)							
No CKD								
ACE-COVID	8	79	5	88	9.2%	1.78 [0.61, 5.22]		
ALPS COVID IP	11	101	9	104	17.2%	1.26 [0.54, 2.91]		
PRAETORIAN-COVID	2	11	1	11	1.9%	2.00 [0.21, 18.98]		
REPLACE COVID	9	61	9	59	17.7%	0.97 [0.41, 2.27]		<b>_</b>
STAR-COVID	8	32	7	32	13.6%	1.14 [0.47, 2.78]		
SWITCH-COVID	4	10	1	7	2.3%	2.80 [0.39, 20.02]		
Telmisartan for treatment of COVID-19	3	66	16	71	29.9%	0.20 [0.06, 0.66]		
All other trials	0	67	0	62		-		
Subtotal (95% CI)		427		434	91.8%	0.95 [0.65, 1.39]		•
Total events	45		48					1
Heterogeneity: $Chi^2 = 10.06$ , df = 6 (P = 0		10%	10					
Test for overall effect: $Z = 0.28$ (P = 0.78	,.							
Total (95% CI)		464		469	100.0%	0.96 [0.67, 1.38]		•
Total events	50		52					Ĩ
Heterogeneity: $Chi^2 = 10.10$ , df = 8 (P = 0		21%	52				<b>—</b>	
Test for overall effect: $Z = 0.22$ (P = 0.82		-170					0.01	0.1 1 10 1
Test for subgroup differences: $Chi^2 = 0.02$	,	P = 0.82	$2)  ^2 = 0%$					Favours RASI Favours control

# Figure S17: All-Cause Mortality - Smoker vs Non-Smoker

	RAS	I I	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-H, Fixed, 95% CI
Ever smoked								
PRAETORIAN-COVID	2	3	1	5	4.1%	3.33 [0.49, 22.90]		
REPLACE COVID	2	23	2	29	9.6%	1.26 [0.19, 8.28]		
STAR-COVID	2	6	2	8	9.3%	1.33 [0.26, 6.94]		
All other trials	0	4	0	3		-		
Subtotal (95% CI)		36		45	22.9%	1.66 [0.59, 4.65]		
Total events	6		5					
Heterogeneity: Chi <sup>2</sup> = 0.65, df = 2 (P = 0.7	'2); l <sup>2</sup> = 0 <sup>4</sup>	%						
Test for overall effect: Z = 0.96 (P = 0.34)								
Non smoker								
COVID MED	1	5	0	1	4.1%	1.00 [0.06, 15.99]		
REPLACE COVID	9	52	8	48	45.0%	1.04 [0.44, 2.47]		<b>_</b>
STAR-COVID	6	26	5	24	28.1%	1.11 [0.39, 3.16]		
All other trials	0	17	0	14		-		
Subtotal (95% CI)		100		87	77.1%	1.06 [0.55, 2.03]		<b>•</b>
Total events	16		13					
Heterogeneity: Chi <sup>2</sup> = 0.01, df = 2 (P = 0.9	99); l <sup>2</sup> = 0	%						
Test for overall effect: Z = 0.18 (P = 0.86)								
Total (95% CI)		136		132	100.0%	1.20 [0.69, 2.07]		•
Total events	22		18					
Heterogeneity: Chi <sup>2</sup> = 1.24, df = 5 (P = 0.9	94); l <sup>2</sup> = 0	%						
Test for overall effect: $Z = 0.65$ (P = 0.52)	-						0.01	0.1 1 10 10 Favours RASI Favours control
Test for subgroup differences: Chi <sup>2</sup> = 0.51		P = 0.4	7), l <sup>2</sup> = 0%	, D				TAVOUIS MAST FAVOUIS COILLIO

## Figure S18: Meta-regression of loss to follow-up versus all-cause mortality



Regression of Log risk ratio on Loss to Follow-up

Figure S19: Network Meta-analysis comparing control vs ACEi or ARB – Mortality Risk Ratio with 95%CI.





Figure S20: Network Meta-analysis comparing control, ACEi and ARB Rankogram Plot -Probability of having a specific rank.



# Figure S21: Cerebrovascular Events


	RAS	61	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
ACE-COVID	2	100	0	104	14.2%	5.20 [0.25, 106.95]	
BRACE CORONA	3	325	3	334	85.8%	1.03 [0.21, 5.05]	
All other trials	0	346	0	337		-	
Total (95% CI)		771		775	100.0%	1.62 [0.43, 6.15]	
Total events	5		3				
Heterogeneity: Chi <sup>2</sup> =	0.88, df =	1 (P = (	0.35); I² =	0%		H	.01 0.1 1 10 100
Test for overall effect:	Z = 0.71 (	P = 0.4	8)			0.	Favours [RASI] Favours [control]

#### Figure S22: Congestive Cardiac Failure

#### (A) Random Effects

	RAS	I	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
BRACE CORONA	16	325	14	334	49.4%	1.17 [0.58, 2.37]	— <b>—</b> —
RAAS-COVID	1	25	7	21	27.6%	0.12 [0.02, 0.90]	
REPLACE COVID	2	75	1	77	23.0%	2.05 [0.19, 22.17]	
All other trials	0	245	0	239		-	
Total (95% CI)		670		671	100.0%	0.71 [0.16, 3.17]	
Total events	19		22				
Heterogeneity: Tau <sup>2</sup> =	1.05; Chi²	= 4.96	, df = 2 (F	<b>9</b> = 0.08	8); l² = 60%	, D	
Test for overall effect:	Z = 0.45 (F	<b>P</b> = 0.6	6)				0.01 0.1 1 10 100 Favours [RASI] Favours [control]

#### (B) Fixed Effects



# Figure S23: Venous Thromboembolism

	RAS	61	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
BRACE CORONA	4	325	6	334	77.7%	0.69 [0.20, 2.41]	
COVID MED	1	9	0	3	9.4%	1.20 [0.06, 23.70]	•
REPLACE COVID	4	75	1	77	13.0%	4.11 [0.47, 35.90]	
All othe trials	0	337	0	340		-	
Total (95% CI)		746		754	100.0%	1.18 [0.45, 3.05]	-
Total events	9		7				
Heterogeneity: Chi <sup>2</sup> =	1.99, df =	2 (P = 0	0.37); l² =	0%			
Test for overall effect:	Z = 0.33 (	P = 0.7	4)				0.01 0.1 1 10 100 Favours [RASI] Favours [control]

# Figure S24: Hospitalisation

	RAS	51	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
ALPS-COVID OP	3	58	1	59	32.2%	3.05 [0.33, 28.49]	
COVERAGE France	3	36	2	33	67.8%	1.38 [0.24, 7.72]	
Total (95% CI)		94		92	100.0%	1.92 [0.50, 7.35]	
Total events	6		3				
Heterogeneity: Chi <sup>2</sup> = (	0.31, df =	1 (P = (	0.58); I² =	0%			0.01 0.1 1 10 100
Test for overall effect:	Z = 0.95 (	P = 0.3	4)				Favours [RASI] Favours [control]

## Figure S25: ICU admission –Start vs Continue/Discontinue Trials

	RAS	l i	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% CI
Start								
ALPS COVID IP	36	101	28	104	32.3%	1.32 [0.88, 2.00]		+=-
ALPS-COVID OP	1	58	1	59	1.2%	1.02 [0.07, 15.88]		
ARB use to minimize respiratory failure	1	16	2	15	2.4%	0.47 [0.05, 4.65]		
COVID MED	4	9	0	3	0.8%	3.60 [0.25, 52.60]		
PRAETORIAN-COVID	1	11	2	12	2.2%	0.55 [0.06, 5.21]		
Telmisartan for treatment of COVID-19	6	78	15	80	17.4%	0.41 [0.17, 1.00]		
All other trials	0	36	0	33		-		
Subtotal (95% CI)		309		306	56.3%	1.00 [0.71, 1.42]		<b>•</b>
Total events	49		48					
Heterogeneity: $Chi^2 = 7.17$ , df = 5 (P = 0.	21): $ ^2 = 30$	1%						
Test for overall effect: Z = 0.01 (P = 0.99	)							
Continue/Discontinue								
ACE-COVID	18	100	20	104	23.0%	0.94 [0.53, 1.66]		
RAAS-COVID	0	25	1	21	1.9%	0.28 [0.01, 6.58]		
REPLACE COVID	16	75	14	77	16.2%	1.17 [0.62, 2.23]		
SWITCH-COVID	4	10	2	8	2.6%	1.60 [0.39, 6.62]		
Subtotal (95% CI)		210		210	43.7%	1.04 [0.69, 1.55]		<b>•</b>
Total events	38		37					
Heterogeneity: Chi <sup>2</sup> = 1.28, df = 3 (P = 0.	73); l <sup>2</sup> = 09	6						
Test for overall effect: Z = 0.17 (P = 0.87	)							
Total (95% CI)		519		516	100.0%	1.02 [0.78, 1.32]		. ↓
Total events	87		85			_		
Heterogeneity: Chi <sup>2</sup> = 8.43, df = 9 (P = 0.	49); l <sup>2</sup> = 09	6						
Test for overall effect: Z = 0.12 (P = 0.90							0.01	0.1 1 10 10 Favours RASI Favours control
Test for subgroup differences: Chi <sup>2</sup> = 0.0	<i>,</i>	= 0.91	). $l^2 = 0\%$					Favours RASI Favours control

### Figure S26: Mechanical Ventilation –Start vs Continue/Discontinue Trials

	RAS	1	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	1	M-H, Fixed, 95% CI
Start								
ALPS COVID IP	21	101	17	104	18.1%	1.27 [0.71, 2.27]		
ARB use to minimize respiratory failure	1	16	1	15	1.1%	0.94 [0.06, 13.68]		
COVID MED	4	9	0	3	0.8%	3.60 [0.25, 52.60]		
Evaluation of the effects of losartan in COVID-19	8	41	9	39	10.0%	0.85 [0.36, 1.97]		
PRAETORIAN-COVID	0	11	2	12	2.6%	0.22 [0.01, 4.07]		
STAR-COVID	8	32	6	32	6.5%	1.33 [0.52, 3.41]		
Telmisartan for treatment of COVID-19	4	78	4	80	4.3%	1.03 [0.27, 3.96]		
All other trials	0	94	0	92		-		
Subtotal (95% CI)		382		377	43.3%	1.13 [0.77, 1.66]		<b>•</b>
Total events	46		39					
Heterogeneity: $Chi^2 = 2.71$ , df = 6 (P = 0.84); $I^2 = 0\%$								
Test for overall effect: $Z = 0.61$ (P = 0.54)								
Continue/Discontinue								
ACE-COVID	8	100	10	104	10.6%	0.83 [0.34, 2.02]		
BRACE CORONA	25	325	32	334	34.1%	0.80 [0.49, 1.32]		
RAAS-COVID	1	25	2	21	2.3%	0.42 [0.04, 4.31]		
REPLACE COVID	10	75	8	77	8.5%	1.28 [0.54, 3.07]		
SWITCH-COVID	3	10	1	8	1.2%	2.40 [0.30, 18.89]		
Subtotal (95% CI)		535		544	56.7%	0.90 [0.62, 1.31]		◆
Total events	47		53					
Heterogeneity: Chi <sup>2</sup> = 2.14, df = 4 (P = 0.71); l <sup>2</sup> = 0%								
Test for overall effect: Z = 0.56 (P = 0.58)								
Total (95% CI)		917		921	100.0%	1.00 [0.76, 1.31]		▲
Total events	93	÷.,	92					Ţ
Heterogeneity: Chi <sup>2</sup> = 5.55, df = 11 (P = 0.90); $I^2 = 0$ %			92				<b>—</b>	
Test for overall effect: $Z = 0.02$ (P = 0.99)	D						0.01	0.1 1 10 10
Test for subgroup differences: $Chi^2 = 0.69$ )	0.44	12 - 00/						Favours RASI Favours control

# Figure S27: Hypotension requiring Inotropes by COVID-19 severity

	RAS	1	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% Cl
Severe disease							
ALPS COVID IP	11	22	6	21	22.3%	1.75 [0.79, 3.88]	+
COVID MED	3	5	0	1	2.7%	2.33 [0.19, 28.25]	
REPLACE COVID	3	9	1	10	3.4%	3.33 [0.42, 26.58]	
STAR-COVID	6	32	6	32	21.8%	1.00 [0.36, 2.77]	
Subtotal (95% CI)		68		64	50.3%	1.56 [0.88, 2.79]	
Total events	23		13				
Heterogeneity: Chi <sup>2</sup> =		`		0%			
Test for overall effect:	Z = 1.52 (	P = 0.1	3)				
Moderate							
ALPS COVID IP	8	79	7	83	24.8%	1.20 [0.46, 3.16]	
REPLACE COVID	3	28	2	25	7.7%	1.34 [0.24, 7.38]	
All other trials	0	12	0	9		-	
Subtotal (95% CI)		119		117	32.5%	1.23 [0.53, 2.86]	-
Total events	11		9				
Heterogeneity: Chi <sup>2</sup> =	0.01, df =	1 (P = (	0.91); l² =	0%			
Test for overall effect:	Z = 0.49 (	P = 0.6	2)				
Mild							
REPLACE COVID	3	38	5	42	17.3%	0.66 [0.17, 2.59]	
All other trials	0	60	0	60			
Subtotal (95% CI)		98		102	17.3%	0.66 [0.17, 2.59]	
Total events	3		5			0.000 [01.11, 2.000]	
Heterogeneity: Not ap			0				
Test for overall effect:		P = 0.5	5)				
Total (95% CI)		285		283	100.0%	1.30 [0.83, 2.04]	
Total (95% CI)	37	200	27	203	100.0%	1.30 [0.03, 2.04]	
Heterogeneity: Chi <sup>2</sup> =		6 (D - (		00/			
Heterogeneity: Chi- = Test for overall effect:		•		0%			0.01 0.1 1 10 1
					.51), I² = 0		Favours RASI Favours control

## **Figure S28: Inotropes – Start vs Continue/Discontinue Trials**

	RAS	1	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-H, Fixed, 95% Cl
Start								
ALPS COVID IP	19	101	13	104	20.4%	1.50 [0.79, 2.88]		+
COVID MED	3	9	0	3	1.1%	2.80 [0.18, 42.80]		
STAR-COVID	6	32	6	32	9.5%	1.00 [0.36, 2.77]		
All other trials	0	172	0	172		-		
Subtotal (95% CI)		236		231	31.0%	1.40 [0.82, 2.39]		◆
Total events	28		19					
Heterogeneity: Chi <sup>2</sup> = 0.71, df = 2	$(P = 0.70); I^2 = 0$	6						
Test for overall effect: Z = 1.23 (P	= 0.22)							
Continue/Discontinue								
ACE-COVID	4	100	8	104	12.5%	0.52 [0.16, 1.67]		
BRACE CORONA	23	325	28	334	43.9%	0.84 [0.50, 1.43]		
REPLACE COVID	9	75	8	77	12.6%	1.16 [0.47, 2.83]		
All other trials	0	10	0	8		-		
Subtotal (95% CI)		510		523	69.0%	0.84 [0.55, 1.28]		•
Total events	36		44					
Heterogeneity: Chi <sup>2</sup> = 1.13, df = 2	$(P = 0.57)$ ; $I^2 = 0^{\circ}$	6						
Test for overall effect: Z = 0.80 (P		-						
Total (95% CI)		746		754	100.0%	1.01 [0.73, 1.41]		•
Total events	64		63			- ' -		
Heterogeneity: $Chi^2 = 3.75$ , df = 5	(P = 0.59); I <sup>2</sup> = 09	6						
Test for overall effect: Z = 0.09 (P							0.01	0.1 1 10 10 Favours RASI Favours control
Test for subgroup differences: Chi	,	0 - 0 16	5) $l^2 = 52$	Q0/_				Favours RASI Favours control

## Figure S29: Acute Kidney Injury – Start vs Continue/Discontinue Trials

	RAS	1	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Start							
ALPS COVID IP	19	101	11	104	61.7%	1.78 [0.89, 3.55]	+∎-
COVID MED	1	9	0	3	4.1%	1.20 [0.06, 23.70]	
STAR-COVID	5	32	2	32	11.4%	2.50 [0.52, 11.96]	
All other trials	0	94	0	92		-	
Subtotal (95% CI)		236		231	77.2%	1.85 [1.00, 3.44]	◆
Total events	25		13				
Heterogeneity: Chi <sup>2</sup> = (	0.24, df = 3	2 (P = 0	0.89); I <sup>2</sup> =	0%			
Test for overall effect:	Z = 1.96 (	P = 0.0	5)				
Continue/Discontinue	9						
ACE-COVID	1	100	0	104	2.8%	3.12 [0.13, 75.67]	
REPLACE COVID	3	75	3	77	16.9%	1.03 [0.21, 4.93]	
SWITCH-COVID	2	10	0	8	3.1%	4.09 [0.22, 74.78]	
All other trials	0	25	0	21		-	
Subtotal (95% CI)		210		210	22.8%	1.70 [0.51, 5.74]	
Total events	6		3				-
Heterogeneity: Chi <sup>2</sup> = (	0.89. df = 1	2 (P = (	).64): l <sup>2</sup> =	0%			
Test for overall effect:	,	·					
Total (95% CI)		446		441	100.0%	1.82 [1.05, 3.16]	
Total events	31		16				•
Heterogeneity: $Chi^2 = 2$		5 (P = (		0%			
Test for overall effect:		`		0 /0			0.01 0.1 1 10 100
Test for subgroup diffe	(		,	(P = 0	$90) l^2 = 0$	1%	Favours RASI Favours control
reactor adogroup diffe	Tences. C		01, ui – 1	() = 0			

# Figure S30: Acute Kidney Injury – Severity of COVID-19

	RAS	51	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Severe disease							
ALPS COVID IP	6	22	4	20	23.9%	1.36 [0.45, 4.14]	
COVID MED	1	5	0	1	4.3%	1.00 [0.06, 15.99]	
REPLACE COVID	2	9	2	10	10.8%	1.11 [0.19, 6.34]	
STAR-COVID	5	32	2	32	11.4%	2.50 [0.52, 11.96]	
Subtotal (95% CI)		68		63	50.3%	1.54 [0.71, 3.31]	
Total events	14		8				
Heterogeneity: Chi <sup>2</sup> =	0.64, df =	3 (P = 0	0.89); I² =	0%			
Test for overall effect:	Z = 1.10 (	P = 0.2	7)				
Moderate							
ALPS COVID IP	13	79	7	83	38.9%	1.95 [0.82, 4.64]	+
REPLACE COVID	0	25	1	28	8.1%	0.37 [0.02, 8.73]	
All other trials	0	14	0	10		-	
Subtotal (95% CI)		118		121	47.0%	1.68 [0.74, 3.79]	
Total events	13		8				
Heterogeneity: Chi <sup>2</sup> =	0.99, df =	1 (P = (	0.32); l <sup>2</sup> =	0%			
Test for overall effect:	Z = 1.25 (	P = 0.2	1)				
Mild							
REPLACE COVID	1	38	0	42	2.7%	3.31 [0.14, 78.84]	
All other trials	0	66	0	68		-	
Subtotal (95% CI)		104		110	2.7%	3.31 [0.14, 78.84]	
Total events	1		0				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.74 (	P = 0.4	6)				
Total (95% CI)		290		294	100.0%	1.65 [0.95, 2.86]	•
Total events	28		16				
Heterogeneity: Chi <sup>2</sup> =		6 (P = (		0%			
Test for overall effect:							0.01 0.1 1 10 10
	,		,	( <b>D</b> 0	.90), l <sup>2</sup> = 0		Favours RASI Favours control